Utilização da procalcitonina sérica como biomarcador para otimização da terapêutica antimicrobiana em doentes queimados by Cabral, José Luís de Almeida
 Universidade de 
Aveiro 
2018 
 Departamento de Ciências Médicas 
José Luís de Almeida 
Cabral 
Utilização da procalcitonina sérica como 
biomarcador para otimização da terapêutica 
antimicrobiana em doentes queimados 
The use of serum procalcitonin as a biomarker for 
antimicrobial stewardship in burn patients 
ii 
 
Universidade de 
Aveiro 
2018 
 Departamento de Ciências Médicas 
José Luís de Almeida 
Cabral 
Utilização da procalcitonina sérica como 
biomarcador para otimização da terapêutica 
antimicrobiana em doentes queimados  
The use of serum procalcitonin as a biomarker for 
antimicrobial stewardship in burn patients 
Tese apresentada à Universidade de Aveiro para cumprimento dos requisitos 
necessários à obtenção do grau de Doutor em Ciências e Tecnologias da 
Saúde - realizada sob a orientação científica do Professor Doutor José Artur 
Paiva, Professor Associado Convidado do Departamento de Medicina da 
Faculdade de Medicina da Universidade do Porto, e Professor Doutor José Luís 
de Almeida, Professor Afiliado do Departamento de Farmacologia e 
Terapêutica da Faculdade de Medicina da Universidade do Porto.
iii 
Para o João 
Para a Ana 
Para a Marta 
iv 
o júri
presidente 
vogal 
vogal 
vogal 
vogal 
vogal 
Professor Doutor José Rodrigues Ferreira da Rocha 
Professor Catedrático, Universidade de Aveiro 
Professor Doutor Nelson Fernando Pacheco da Rocha 
Professor Catedrático, Universidade de Aveiro 
Professor Doutor António Carlos Megre Eugénio Sarmento 
Professor Catedrático Convidado, Universidade do Porto 
Professor Doutor José Artur Osório de Carvalho Paiva 
Professor Associado, Universidade do Porto 
Professor Doutor Manuel do Rosário Caneira da Silva 
Professor Auxiliar Convidado, Universidade de Lisboa 
Professor Doutor João Gonçalves Pereira 
Professor Auxiliar Convidado, Universidade Nova de Lisboa 
agradecimentos A realização de uma Tese de Doutoramento implica, além do natural esforço e 
empenho do seu autor, a colaboração de várias pessoas, quer através da participação 
directa ou indireta nos diferentes passos da mesma, quer pelo seu incentivo ou tão só 
pela sua paciência, durante um caminho nem sempre fácil e em que as dúvidas e os 
períodos de menor ânimo são uma constante. Levar a cabo um empreendimento desta 
natureza torna-se ainda mais difícil quando cumulativamente há que atender outras 
responsabilidades a nível profissional exigindo tanta dedicação e tempo como a 
atividade médica em geral, no meu caso particular com acrescidas funções de 
coordenação clínica e cirúrgica de uma Unidade de Queimados. O presente trabalho 
pode ser visto neste contexto como resultado do empenho de uma equipa não 
institucionalizada, mas real e ativa, sendo da mais elementar justiça manifestar aqui a 
minha profunda gratidão a todos os que generosamente me apoiaram neste projeto.  
Sendo impossível agradecer discriminadamente a todos os que de uma ou outra forma 
me acompanharam durante este percurso, não poderia, mesmo sob o risco de 
omissões involuntárias, pelas quais desde já peço as maiores desculpas, deixar de ter 
uma palavra de especial reconhecimento àqueles que foram no fundo os grandes 
responsáveis pela sua conclusão: 
- ao Professor Doutor José Artur Paiva, meu Orientador, pela confiança que depositou
em mim, pela exigência de qualidade e rigor científico a que me habituou, pela sua boa
disposição e disponibilidade para me atender no meio das suas múltiplas tarefas;
- ao Professor Doutor José Luís de Almeida, também meu Orientador e particular
amigo, igualmente um homem de atividade constante, pela generosidade com que
sempre me apoiou, pela orientação segura nos momentos certos e por também ele ser
um exemplo de que é possível fazer ciência de alto nível em Portugal;
- ao Professor Doutor Nelson Rocha, Coordenador do Programa Doutoral em Ciências
e Tecnologias da Saúde, pela simpatia, pelos conselhos oportunos e por toda ajuda
prestada na resolução das vicissitudes de todo o meu percurso doutoral;
- à Professora Doutora Vera Afreixo, sem a qual esta tese não teria sido escrita, pelo
inestimável apoio que me dispensou nas análises estatísticas e, mais importante ainda,
pela sua bondade, pela paciência que teve comigo e pela amizade incondicional que se
criou no meio das nossas discussões científicas e que nos tornou irmãos para a vida;
- aos outros co-autores dos artigos desta tese, Dr. Filipe Santos, Dr.ª Rita Meireles, Dr.
Miguel Vaz, Dr.ª Catarina Chaves, Dr.ª Marisa Caetano, Dr.ª Margarida Marques, Dr.ª
Isabel Tourais e Professor Doutor João Frade, pela sua generosa colaboração, pelo
incentivo e pela amizade com que me têm brindado;
- ao Dr. Celso Cruzeiro, meu Amigo e meu Mestre, por tudo que com ele aprendi, pelo
incentivo constante, pelo apoio generoso e indefectível em todas horas;
- aos meus Amigos de sempre: de Arouca, do Porto, de Coimbra e de Aveiro, por tudo
o que vivemos juntos e por nunca deixarem de acreditar em mim;
- aos meus Pais e Irmãos, por estarem sempre no meu coração, por tudo que me
deram e por tudo que lhes devo;
- aos meus Filhos, a parte melhor da minha vida, por todo o seu amor e compreensão,
pelos seus sorrisos, por todas as alegrias, por todo carinho e ternura que me têm dado;
- aos Doentes Queimados, a quem tenho dedicado a minha vida profissional, e cujo
sofrimento e necessidades são tantas vezes ignorados, esperando que de alguma
forma este trabalho possa contribuir para melhorar o seu tratamento e a sua qualidade
de vida.
v 
vi 
palavras-chave queimaduras, sepsis, biomarcadores, procalcitonina, terapêutica 
antimicrobiana 
resumo A sepsis, desencadeando disfunção multiorgânica, é a principal causa de 
morte em doentes queimados, pelo que a instituição de terapêutica 
antimicrobiana precoce e apropriada é fundamental. Todavia, a dificuldade em 
distinguir entre um quadro de sepsis verdadeira e uma resposta inflamatória 
fisiológica à queimadura faz com que muitas vezes o tratamento inicial destes 
doentes não seja o mais adequado, causando um atraso no início da 
terapêutica, aumentando a mortalidade ou levando à prescrição antimicrobiana 
supérflua, com consequente aumento da incidência de efeitos adversos e 
resistências microbianas. Diversos biomarcadores clínicos e/ou laboratoriais 
têm sido utilizados para ajudar no diagnóstico de sepsis em outros contextos, 
particularmente a nível dos Serviços de Urgência e de Cuidados Intensivos. 
Entre os biomarcadores habitualmente disponíveis, a procalcitonina (PCT) é 
reconhecida como sendo a mais fiável para essa função. O objetivo principal 
desta tese consistiu na avaliação do potencial papel da PCT nos protocolos de 
otimização da terapêutica antimicrobiana em doentes queimados. 
Com base numa amostra de doentes de uma Unidade de Queimados de um 
hospital terciário, e utilizando uma definição de sepsis específica para este tipo 
de doentes, demonstrou-se que a PCT foi superior aos biomarcadores 
tradicionais (contagem leucocitária, contagem plaquetária, protrombinemia, D-
dímeros, proteína C-reativa, lactato sérico e temperatura) no diagnóstico 
precoce de sepsis. Foi proposto um limiar de 0,5 ng/mL como determinante da 
necessidade de avaliação diária da PCT, sendo recomendada terapia 
antimicrobiana empírica acima de 1,0-1,5 ng/mL. A PCT demonstrou uma 
correlação forte e estatisticamente significativa com a mortalidade. A 
persistência de valores de PCT elevados durante a terapêutica antimicrobiana 
mostrou correlação com a ineficácia desta, opostamente ao sucedido quando 
esses valores declinaram de forma consistente.  
A cinética da PCT mostrou-se de grande valia para o diagnóstico diferencial 
entre a sepsis e a resposta inflamatória precoce associada a queimaduras, 
bem como para o diagnóstico de sepsis pós-operatória. Os níveis de PCT 
foram significativamente mais elevados em doentes com sepsis por bactérias 
Gram-negativo em comparação com os controlos e com os doentes com um 
quadro de sepsis por bactérias Gram-positivo. A análise de subgrupos 
demonstrou ainda que os valores mais elevados ocorreram em doentes com 
sepsis causada por bactérias Gram-negativas não fermentativas, por 
Klebsiella pneumoniae e, em menor escala, por outras Enterobacteriáceas. 
Valores de PCT inferiores a 0,5 ng/mL praticamente excluíram as infecções 
por bactérias Gram-negativas. 
Enquanto não estiverem facilmente disponíveis métodos de identificação 
microbiológica mais rápidos, mais confiáveis e mais baratos, doseamentos 
seriados da PCT, capacitando as decisões de prescrição, deverão ser 
incluídos nos protocolos de administração antimicrobiana em Unidades de 
Queimados, aumentando a eficácia terapêutica e diminuindo os efeitos 
adversos, as resistências microbianas e os custos.  
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Sepsis, inducing multiorganic dysfunction, is the main cause of death in burn 
patients. A prompt and appropriate selection of antimicrobial therapy is crucial 
for their outcome. The difficulty in distinguishing true sepsis from physiological 
inflammatory response associated to burn injury, strongly contributes to an 
inadequate management of these patients, potentially leading to delayed 
antimicrobial therapy, increased mortality, or to superfluous antimicrobial 
prescription, raising the incidence of adverse events and microbial resistance. 
Several clinical and/or laboratorial biomarkers have been used to help 
clinicians to distinguish sepsis from systemic inflammatory response, namely at 
the Emergency and Intensive Care Departments. Among the available 
biomarkers, procalcitonin (PCT) is recognized as the most reliable for this 
purpose. The main objective of this thesis was to investigate the potential role 
of PCT as part of antimicrobial stewardship programs in burn patients.  
Taking a sample of patients from a Burn Unit of a tertiary care hospital and 
using specific burn sepsis definition, the results showed that PCT compared 
with traditional biomarkers (leucocyte and platelet countings, prothrombinemia, 
D-dimers, C-reactive protein, serum lactate and temperature) was the best
biomarker for an early diagnosis of sepsis. An alert cut-off of 0.5 ng/mL was
proposed as reason for daily PCT assessment, with empirical antimicrobial
therapy recommended for values above 1.0-1.5 ng/mL. PCT demonstrated a
close and statistically significant correlation with the mortality. Sustained
increased values during antimicrobial therapy showed a correlation with
therapeutic failure, as opposed to what happened when PCT levels consistently
fell.
PCT kinetics proved to be of great value for the differential diagnosis between 
sepsis and early inflammatory response associated with burn injury as well as 
for the diagnosis of postoperative sepsis in these patients. PCT levels were 
found to be significantly higher in patients with Gram-negative sepsis 
comparing to patients with Gram-positive sepsis and controls. Subgroup 
analysis showed that the most elevated values occurred in patients with sepsis 
caused by non-fermentative Gram-negative bacteria, by Klebsiella pneumoniae 
and, in a lesser extent, by other Enterobacteriaceae. PCT values under 0.5- 
ng/mL almost excluded infections due to Gram-negative bacteria.  
While faster, more reliable and cheaper methods of microbiological 
identification are not developed and widely available, repeated PCT 
measurements, coupled with careful anamnesis and clinical examination, 
empowering prescription decisions, should be included in antimicrobial 
stewardship programs in Burn Units in order to increase antimicrobials 
effectiveness, to reduce mortality, to avoid adverse events and the 
development of microbial resistance, and to minimize the financial burden.
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1. Background
1.1. Sepsis is the main cause of death in burn patients 
Severe burn injuries, affecting all body systems and their regulatory pathways, may be 
considered as a paradigm of polytraumatism. Tissue injury, coupled with the release of 
multiple local and systemic mediators of inflammation, leads to an increase in vascular 
permeability, resulting in huge hydroelectrolytic and cardiovascular changes [1]. These 
changes rapidly evolve to a state of hypovolemic shock, with loss of water, proteins and 
electrolytes, which is usually fatal if not adequately treated. In the past, shock used to be the 
first cause of death in these patients. However, the great advances in intensive care in the last 
decades have improved the outcome and the initial acute phase of hypovolemia is overcome 
with success in most cases [2]. Nowadays, sepsis, the systemic infection state evolving to 
multiorganic failure, became the major cause of death in burn patients, generally occurring in 
the late post-traumatic period [3]. 
In the literature, it was referred that burn patients have up to a 3-fold higher prevalence of 
sepsis than other trauma victims [4]. Comparing to other critical patients, severe burn victims 
have a higher susceptibility to complications leading to sepsis, due to intrinsic and extrinsic 
factors [5,6]. The intrinsic factors include the loss of skin barrier, humoral and cellular 
immunodepression, the presence of necrotic tissue, bacterial translocation and the diminution 
of airway clearance, namely when there is an associated inhalation injury. The extrinsic factors 
comprise the use of invasive devices (intravascular catheters, endotracheal tubes, indwelling 
bladder catheters, etc.), the prolonged immobilization and the exposition to nosocomial flora. 
1.2. The diagnosis of sepsis is complex in the presence of burns 
Sepsis is a multifactorial syndrome in which microbiological agents, individual immune 
response and comorbidities contribute to its development. Sepsis identification is not always 
straightforward, and the progressive changes verified in its diagnostic criteria put in evidence 
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the difficulties found to confirm the diagnosis. In the last international consensus conference, 
held by the Society of Critical Care Medicine (SCCM) and by the European Society for Intensive 
Care Medicine (ESICM) in 2016, sepsis was defined as life-threatening organ dysfunction 
caused by a deregulated host response to infection (Sepsis 3) [7]. Host dysfunction is 
suspected by the presence of an acute change in the quick Sequential Organ Failure 
Assessment score equal or above 2 points (Table 1). 
Table 1. Criteria for the suspicion of sepsis 
   qSOFA (quick Sequential Organ Falency Assessment) ≥ 2 
    Respiratory rate ≥ 25/min 
    Altered mentation (Glasgow Coma Scale < 13) 
    Systolic blood pressure ≤ 100 mmHg 
+ 
 Documented Infection 
    Positive blood culture or 
    Deep tissue invasion (biopsy with > 105 cfu/g) or 
    Imagiologically documented infection (X-ray, CT scan, MR scan) or 
    Clinical response to antimicrobials 
cfu – colony forming unit; CT – computed tomography; MR – magnetic resonance 
In large burns, the clinical signs and laboratorial findings usually taken to diagnose infection 
are somewhat confusing and even more difficult to interpret due to the magnitude of the 
systemic inflammatory response triggered by the burn lesion, which mimics a true septic 
episode. For instance, hyperthermia is frequent in burn patients due to a deregulation of the 
thermoregulatory centre induced by the burns, and leucocytosis may not be linked to anti-
infectious response, particularly in post-operatory situations. Moreover, Sepsis 3 definition has 
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not yet been validated for burn sepsis. Currently, the most used criteria for the diagnosis of 
burn sepsis are still those proposed in 2007 by the American Burn Association, specifying cut-
offs for clinical signs and requiring documented microbiological identification [8] (Table 2).  
Table 2. American Burn Association definition for sepsis in adult burn patients 
 Clinical Criteria (≥ 3)
    Axillary temperature > 39 ºC or < 36.5 ºC 
    Heart rate > 110/minute 
    Respiratory rate > 25/min (> 12 L/min if ventilated) 
    Thrombocytopenia < 100,000/µL 
 Hyperglycaemia (if no pre-existing diabetes mellitus): 
 Plasma glucose > 200 mL in non insulin-treated patients 
 Insulin resistance in insulin-treated patients (>7 UI insulin/h) 
 Inability to enteral feeding > 24 h 
  Abdominal distension 
  Enteral feeding intolerance 
  Uncontrollable diarrhoea (> 2,500 mL/day) 
+
 Documented Infection 
    Positive blood culture or 
    Deep tissue invasion (biopsy with > 105 cfu/g) or 
    Imagiologically documented infection (X-ray, CT scan, MR scan) or 
    Clinical response to antimicrobials 
UI – international unit; cfu – colony forming unit; CT – computed tomography; MR – magnetic resonance 
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A major problem is that for most burn treatment facilities the actual conditions for definitive 
identification of microbiological agents in patient samples are time-requiring, taking 2 to 4 
days to deliver results [9]. 
1.3. Adequate and prompt administration of antimicrobial therapy reduces 
mortality 
As stated by Kumar [10] and confirmed by many other studies, the prompt administration of 
an adequate antimicrobial therapy, i.e. the right dose of the most effective drug against the 
causative microorganism(s) in the most appropriate pharmacokinetic and pharmacodynamic 
conditions, is the most important single factor for the survival of the septic patient, and any 
delay in antimicrobial therapy is associated with increased mortality. This is particularly true in 
burn patients who are immunodepressed and have a deficient general state due to 
hypermetabolism and hypercatabolism and constant loss of proteins, hydration, electrolytes 
and warm from the denuded areas until their new full cutaneous covering is assured [11,12]. 
Burn physicians are, therefore, urged to start antimicrobial therapy at the first evidence of 
infection, a decision that requires a thorough clinical assessment and remarkable clinical 
expertise.  
1.4.  Unnecessary antimicrobial therapy promotes microbiological resistance 
In the presence of an adequate antimicrobial therapy, microbial countings will fall, making it 
possible for the body systems to control and resolve the infectious episode. This is, however, a 
dynamic process:  microbes struggle to survive and even with the most effective drugs, there 
are some microorganisms that will be able to resist to the antimicrobials and spread the 
mechanism of resistance to other bacteria. To reduce the possibility of emergence and 
selection of microbial resistance, besides the prompt beginning of the antimicrobial therapy at 
the first evidence of infection, it is crucial to focus the spectrum of the drug on the pathogen 
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and to limit the duration of the treatment to the strictly necessary, reducing selective pressure 
[13]. This strategy has additional advantages, e.g. by allowing a reduction of the potential 
adverse events, of the costs and, in most cases, also of the length of hospitalization, provided 
that meanwhile surgical covering of the burns is achieved. 
1.5. The utilization of biomarkers can decisively help antibiotic stewardship 
The impact of an adequate antimicrobial therapy on survival of sepsis patients makes 
mandatory the establishment of an antimicrobial stewardship program to optimize drug 
prescription and reduce microbiological resistance [14,15].  The best strategy couples quick 
identification of infection with timely collection of specimens for microbiological exams and 
institution of a broad microbiological spectrum antimicrobial therapy. With the attainment of 
microbiological identification and susceptibility tests antimicrobial therapy should be changed 
to a narrower spectrum drug capable of attaining cure of the infection and reducing 
deleterious ecological impact (de-escalation) [16,17]. The extension of the treatment will 
ideally be the shortest able to produce cure and avoid infection recurrence, which is not easy 
to define and largely varies for different microorganisms and different patients. Again, even 
taking into account the importance of microbiological confirmation of infection, the delay in 
obtaining the results may give rise to unnecessary and potentially deleterious prolongation of 
therapy. Until the full development and wide availability of new techniques allowing quicker 
microbiological identification is reached, the use of biochemical and/or biophysical markers of 
sepsis [18], obviously linked with sound clinical observation, may help the decision on starting 
and ending the antimicrobial therapy [19], avoiding unnecessary medication, reducing adverse 
side effects of drug therapy and the selection of resistance, decreasing costs [20], and, in many 
cases, diminishing the length of hospitalization of burn patients. 
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1.6. Procalcitonin is one of the best biomarkers for antimicrobial stewardship in 
septic patients 
From a plethora of sepsis biomarkers described in the literature [21], procalcitonin (PCT) is 
certainly one of the most studied in the last decades and allegedly has the best discriminative 
power among the ones generally available at hospital facilities [22,23,24,25]. Regulated by 
CALC-1 gene, PCT is a 116-amino acid peptide precursor of calcitonin, mainly secreted by 
thyroid C cells, and in healthy individuals it is barely detected in blood (< 0.10 ng/mL). In the 
presence of systemic infection, CALC-1 is also expressed in nonthyroidal cells all over the body 
(liver, kidney, adipocytes, etc.) and consequently the levels of PCT suffer a sudden and 
dramatic increase, due to a production in large amounts of PCT that is not cleaved to form 
calcitonin, as occurs in thyroid C-cells, being abruptly released to the bloodstream, till 1000 
times its usual concentration [26]. Serum PCT increase is noticeable just 2-4 hours after sepsis 
onset, peaks at 24-48 hours and its values follow the course of the infection, quickly subsiding 
with the control of the septic process, in average diminishing around 50% every 1-1.5 days 
[27]. PCT has been tested against other available biomarkers, like C-reactive protein (CRP) and 
interleukin IL-6 and it seems to be more accurate and more suitable to diagnose and monitor 
several infectious processes and its treatment [28]. Recent meta-analysis have confirmed a 
good correlation between abnormal PCT levels and the presence of bloodstream infections 
and that elevated PCT levels and also that PCT non-clearance is related with an increased risk 
of sepsis and a higher mortality rate [29,30]. On the other hand, some authors have reported 
that the different composition of the membrane cells of Gram-negative, Gram-positive and 
fungi elicit the activation of different types of cytokines leading to diverse degrees of PCT 
production [31,32]. These different patterns might give some hints about the causative 
microorganisms, while microbiological identification is not available [33]. 
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Considering its fair accuracy for sepsis diagnosis and the correlation of its kinetics with sepsis 
evolution [34], PCT use has been recommended in diverse clinical contexts, such as the 
exclusion of bacterial involvement in lower respiratory infections [35], the diagnosis, 
stratification, prognostic assessment [36,37] and antimicrobial stewardship of septic patients 
[38,39], the diagnosis of postoperative infections [40,41,42]; the differential diagnosis of sepsis 
from diverse microbial origins [43,44], etc.  
The utility of PCT for management of burn patients has, however, been questioned due to its 
mild elevation in localized infections, and to a substantial amount of false positives originated 
by the burn-associated or surgery-associated systemic inflammatory response [45]. These 
would limit its interest for antimicrobial stewardship in burn sepsis patients, which has not 
been adequately studied. Indeed, most of the published literature on the use of PCT rarely 
includes significant number of burn patients, usually analyzed together with other critical care 
patients, with much diverse clinical features and also employing diverse sepsis definitions 
[46,47]. 
In 2007, Tang et al. [48], in a meta-analysis pooling 2,097 patients, in which the presence of 
burns was an exclusion criterion, concluded that their study did not support a widespread use 
of PCT for sepsis diagnosis in critical care settings and stated that this could not be generalized 
to burn patients. In the PASS study [49], performed in 2011, in nine Danish intensive care units 
(ICUs) and including 1,200 patients, most patients came primarily from medical wards and 
there is no reference to the inclusion of burn patients.  In their controversial work, the authors 
concluded that the use of PCT for antibiotherapy escalation did lead to organ-related harm and 
prolonged length-of-stay at the ICU. In spite of it, the study confirmed that PCT levels may be 
taken as a good predictor of mortality. In a study published in 2014, using a sample of 34 burn 
patients with only 16 patients with documented infection, Seoane et al. [50] concluded that 
PCT was not a precise indicator of sepsis. However, besides the reduced sample size, they did 
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not perform an analysis of PCT kinetics, merely using samples from the day of sepsis suspicion, 
the day before and the day after, and no information was provided about potential ongoing 
antimicrobial therapy.  
On the other hand, in 2011, in a meta-analysis by Mann et al. [51] including burn patients 
exclusively, the authors stated that PCT assay can be used to help sepsis diagnosis and to 
reduce antibiotic exposure.  Lavrentieva et al. [52], in a prospective study published in 2012, 
with 145 patients and daily PCT measurement, found that PCT kinetics has great diagnostic and 
prognostic value, and is also a valuable tool in monitoring the efficacy of antimicrobial therapy. 
In 2015, Ren et al. [53] published a meta-analysis, including 566 burn patients from nine trials, 
concluding that, despite some heterogeneity among these studies, PCT was a useful biomarker 
for sepsis diagnosis. 
2. Thesis Aims and Structure
Sepsis, inducing multiorganic dysfunction, is the main cause of death in burn patients. A 
prompt and appropriate selection of antimicrobial therapy is crucial. The difficulty in 
distinguishing true sepsis from physiological inflammatory response to burn injury, strongly 
contributes to an inadequate management of these patients. The main objective of this thesis 
was to investigate the utility of PCT as a biomarker for antimicrobial stewardship in burn 
patients.  
To achieve its goal, the thesis was organised in seven chapters. The first one is the introduction 
of the subject, which is followed by five chapters corresponding to five articles published in 
peer-reviewed, indexed, journals: one meta-analysis assessing PCT use in Burn Units in the 
world and four clinical studies analysing the performance of PCT in different perspectives, 
using samples of burn patients from Coimbra Burns Unit (CBU), from the Plastic Surgery and 
Burns Department of Coimbra University Hospital Centre (Centro Hospitalar e Univesitário de 
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Coimbra – CHUC), in Portugal. The seventh and last chapter is dedicated to global discussion 
and presentation of the conclusions.  
In Chapter 1, the background picture of burn sepsis was drawn, exposing the current concepts 
about its pathophysiology, the difficulties existing for its diagnosis and prognosis as well as the 
complexities associated to its management and the paper that biomarkers, namely PCT, may 
have in this context. PCT potential for the monitoring of antimicrobial therapy efficacy was also 
referred. 
First of all, and in order to appraise the best available evidence, in Chapter 2 the author 
performed a systematic review of medical literature about the utilization of PCT measurement 
in the managing of sepsis in burn patients. Taking in account the scarce number of studies that 
were found, with relatively small and heterogenous populations, a meta-analysis was also 
done fulfilling all the criteria of PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) checklist [54]. Two meta-analysis methods were used to calculate the pooled 
effect estimates: the inverse variance assuming a fixed-effects model, and the DerSimonian-
Laird method assuming a random-effects model. Homogeneity among studies was evaluated 
using the Cochran's Q statistic and the I2 statistic. The publication bias associated with the 
AUC on diagnostic sepsis effect was analysed by the funnel plot and the Egger test. 
Trying to overcome the uncertainty derived from the heterogeneity of populations on the 
existing studies, and its small sample sizes, it was decided to perform a set of clinical studies 
based in a large sample of patients from Coimbra Burn Unit, using the ABA criteria for the 
inclusion/exclusion of patients. A total of four clinical studies, covering different but 
complementary aspects important to assess the role of PCT as biomarker for antimicrobial 
stewardship in burn patients were accomplished, evaluating PCT potential for assessing the 
diagnosis, prognosis, antimicrobial therapy monitoring, and Gram type of causative 
microorganisms in burn sepsis patients. The results were published in indexed and peer-
reviewed scientific journals, and reprints from the published papers are presented in this 
José Luís de Almeida Cabral 
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thesis, corresponding to Chapters 3 to 6. 
In Chapter 3, PCT performance for the early diagnosis of burn sepsis is appraised, using ROC 
(Receiver Operative Characteristics) curves for comparison with other currently employed 
infection biomarkers (leucocyte and platelet countings, prothrombinemia, D-dimers, C-reactive 
protein, serum lactate and temperature), with a view to validating its use for the sepsis 
diagnosis in burn patients. Under a nonparametric approach, the quantitative variables were 
analysed with Mann–Whitney U test and qualitative variables were analysed with Pearson chi-
square test. To measure the effect-size the probability of superiority (PS) was used. A cut-off 
for sepsis diagnosis in this sample of CBU patients was proposed using Youden Index. 
The feasibility of PCT use to predict the outcome and to monitor the efficacy of antimicrobial 
therapy in a sample of severe burn adult patients is sized up in Chapter 4. Again, quantitative 
variables were analysed with Mann–Whitney U test and qualitative variables were analysed 
with Pearson chi-square test, while time variations of PCT levels were tested using Friedman’s 
test and Kendall’s W.  
Chapter 5 presents an observational retrospective study done to investigate whether or not 
the alterations of inflammatory features directly resulting from tissue trauma caused by burns 
in the acute phase, and also due to surgical interventions, would interfere with the ability of 
PCT to distinguish between this pure inflammatory response and septic conditions. 
Comparisons between sepsis and no sepsis groups were performed using the Mann-Whitney 
test for quantitative variables and the Fisher’s exact test for qualitative variables, while time 
comparisons used Friedman’s test. 
In Chapter 6, the accuracy of PCT to distinguish sepsis caused by Gram-negative and Gram-
positive bacteria in burn patients is assessed. Kruskall–Wallis and Mann–Whitney tests were 
used to compare quantitative variables. Qualitative variables were compared with the Pearson 
chi-square test. For pairwise comparisons, the Bonferroni correction was applied. ROC curves 
were performed, paying attention to the areas under the curve (AUC) for Gram negative and 
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Gram-positive sepsis and subgroup analysis according to the most common microorganisms in 
each group were also done. 
Chapter 7 is dedicated to the integrated discussion of the studies described above, finally 
drawing and presenting the conclusions on the usefulness PCT for antimicrobial stewardship in 
Burn Units. 
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Abstract
The continuous development of resuscitation techniques and intensive care reduced the
mortality rate induced by the initial shock in burn patients and, currently, infections (espe-
cially sepsis) are the main causes of mortality of these patients. The misuse of antimicrobial
agents is strongly related to antimicrobial and adverse patient outcomes, development of
microbial resistance and increased healthcare-related costs. To overcome these risks, anti-
microbial stewardship is mandatory and biomarkers are useful to avoid unnecessary medi-
cal prescription, to monitor antimicrobial therapy and to support the decision of its stop.
Among a large array of laboratory tests, procalcitonin (PCT) emerged as the leading bio-
marker to accurately and time-effectively indicate the presence of systemic infection. In the
presence of systemic infection, PCT blood levels undergo a sudden and dramatic increase,
following the course of the infection, and quickly subside after the control of the septic pro-
cess. This work is a meta-analysis on PCT performance as a biomarker for sepsis. This
meta–analysis showed that overall pooled area under the curve (AUC) is 0.83 (95% CI =
0.76 to 0.90); the estimated cut-off is 1.47 ng/mL. The overall sepsis effect in PCT levels
is significant and strong (Cohen’s d is 2.1 and 95% CI = 1.1 to 3.2). This meta–analysis
showed PCT may be considered as a biomarker with a strong diagnostic ability to discrimi-
nate between the septic from the non-septic burn patients. Thus, this work encourages the
determination of PCT levels in clinical practice for the management of these patients, in
order to timely identify the susceptibility to sepsis and to initiate the antimicrobial therapy,
improving the patients’ outcomes.
Introduction
Comparing to other critical patients, severe burn victims have a higher susceptibility to
develop infectious complications leading to sepsis, which is the major cause of mortality in
these patients, and may result from intrinsic and extrinsic factors [1,2]. The former may
include loss of skin barrier, humoral and cellular immunodepression, presence of necrotic
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tissue, bacterial translocation and diminution of airway clearance when inhalation injuries are
associated. The later comprise the use of invasive devices (intravascular catheters, endotracheal
tubes, indwelling bladder catheters, etc.), immobilization and exposition to nosocomial flora
[2,3].
Clinical signs and laboratorial findings commonly used to diagnose the presence of infec-
tion are not specific and are difficult to interpret due to the magnitude of the systemic inflam-
matory response unfettered by large burns, which mimics a septic episode. The consensus
international definition of sepsis, formulated by the American College of Chest Physicians and
by the Society of Critical Care Medicine (ACCP/SCCM) [4,5], was subjected to a revision for
burn patients by the American Burn Association [6] (see Annex 1) [S1 File]. This revision
implied the modification of some cut-offs and the concomitant documentation of microbio-
logical identification. Nevertheless, currently, the definite identification of microbiological
agents still takes two to four days [7]. As stated by Kumar [8] and confirmed by many other
studies, the prompt administration of an adequate antimicrobial therapy is the most important
isolated factor for the survival of the septic patient and any hourly delay is associated with an
increase in mortality.
Burn surgeons are therefore urged to start antimicrobial therapy at the first evidence of
infection, but it requires a strong clinical expertise, attending to the lack of a time-effective
microbiological confirmation. An adequate therapy reduces the microbial counting, which
enables the body systems to control and stop the infectious episode. This is, however, a
dynamic process: there are resistant microorganisms that may survive, even when treated with
the most effective bactericidal agents. Some microorganisms develop mutations capable of
overlapping the antibiotic action, giving rise to microbial resistance (i.e. making the drug inef-
fective), and thus they may spread to other cells and tissues, being responsible for a systemic
infection. To reduce the possibilities of development of microbial resistance is crucial to avoid
unnecessary administration of antimicrobial therapy. On the other hand, the prompt begin-
ning of the therapy, with the right dose of an effective drug at the first evidence of infection is
equally important, so are the selection of the right drug targeting the microbiological agent
and to limit the duration of treatment to the strictly necessary, preventing antibiotic resistance
and selective pressure on the microorganisms [9]. This strategy has additional advantages,
including the reduction of medication side effects, healthcare-related costs and, in most cases,
the length of hospitalization (providing that the surgical treatment of the burns is achieved).
The use of biomarkers has been recommended to help clinicians to timely decide when to
start antimicrobial therapy, to monitor its evolution and to advise its early suspension. From
the currently available biomarkers, procalcitonin (PCT) has shown the greatest accuracy to
indicate the presence of systemic infections within an acceptable timing, in a great range of
clinical scenarios [10–12].
This work is an extended and updated version of the paper published by Ren et al. [13] [S2
File], including the overall estimation and discussion of several other effect sizes in PCT levels
and incorporating four other studies. Its aim is to summarize literature data (through meta-
analysis) about the use of PCT for the early detection of sepsis in burn patients, and to discuss
the proposed PCT cut-offs for the diagnosis of sepsis.
Material and Methods
Data source
PubMed, Scopus and Web of Science databases were used. The combined search term used for
this search was: [procalcitonin OR PCT) AND (sepsis OR septic) AND burn]. The search was
performed up to 1st December 2015.
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Data extraction, evaluation and synthesis
Only articles written in English focusing on burn patients and on the evaluation of PCT role
on the diagnosis and monitoring of septic episodes were considered. Titles and abstracts of
records retrieved by the search were screened to determine their relevance. Relevant studies
were reviewed in full text, in order to determine their relevance for the meta-analysis. After
reading titles and eliminating duplicates (LC and VA), 96 abstracts were independently
assessed by three authors (LC, VA and LA), and, from these, 14 references were subjected to
detailed analysis and included in the sample, by consensus or majority decision.
Inclusion and exclusion criteria
A study was considered eligible for inclusion in the meta-analysis if it provided area under the
curve (AUC) on serum PCT for diagnosis of sepsis or the serum PCT levels by sepsis and non-
sepsis groups in burn patients.
Statistical analysis
Two techniques were used to calculate the pooled effect estimates: the inverse variance assuming a
fixed-effects model, and the DerSimonian-Laird method assuming a random-effects model.
Homogeneity among studies was evaluated using the Cochran’s Q statistic and the I2 statistic
(the values of 0.25, 0.50, and 0.75 indicating low, moderate, and high degrees of heterogeneity).
Publication bias was evaluated using the funnel plot and the Egger regression asymmetry test.
To investigate potentially different effects according to the study, subgroup analyses were
performed. Sensitivity analysis to show the impact of each study or subgroup studies on the
results was also held.
Meta-DiSc 1.4 (XI Cochrane Colloquium, Barcelona, Spain) was used to calculate the sum-
mary receiver operating characteristics (SROC) and the pooled AUC [14]. MetaXL 2.0 (Epi-
Gear International Pty Ltd, Wilston, Queensland, Australia) was used to calculate the pooled
Cohen’s d effect sizes (difference of PCT levels between sepsis and non-sepsis groups, the
pooled AUC and pooled mean effects [15].
The weight average of all PCT cut-off for sepsis diagnosis proposed in the studies under
analysis was also measured.
Results
The removal of duplicates from the 160 articles that were initially identified through search in
PubMed, Scopus and Web of Science resulted in 96 individual articles (Fig 1). The great major-
ity did not fulfill the eligibility criteria. After exclusion of ineligible papers, 14 articles, compris-
ing a temporal range from 1997 to 2015, were found to meet the inclusion criteria and were
selected for review.
Plasma PCT concentrations had been measured using different methods, such as PCT-Q
immunochromatography (Brahms Diagnostica, Berlin, Germany) [15,16], PCT-Lumi immu-
noluminometric (Brahms Diagnostica, Berlin, Germany) [16–21], electrochemical lumines-
cence immunoassay (ECLIA) (Brahms Diagnostica, Berlin, Germany) [22–24], and
immunoassay sandwich and final fluorescence technique (VIDAS, bioMe´rieux, Marcy
L’Etoile, France) [25].
Two studies were pediatric [20,26], one mixed [18] and the remaining studies included
only adult patients [15–19,21,23–25,27–29].
Studies also differ in the PCT cut-off defined for sepsis suspicion. Reported cut-off values
include 0.5 ng/mL [23], 0.534 ng/mL [16], 0.69 ng/mL [22], 1.5 ng/mL [19,27], 1.7 ng/ mL
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[23], increment of 1.5 ng/mL in two consecutive days [18], 2 ng/mL [25,29]; 3 ng/mL [17],
and 5 ng/mL [20]. Using the different cut-offs for sepsis diagnosis proposed in each study
(Table 1), the weight average of all PCT cut-offs for sepsis was computed and the resulting cut-
off was 1.59 ng/mL. Fig 2 shows a bubble plot of cut-off for PCT in sepsis diagnosis for 12 stud-
ies organized by year. The two older studies showed the highest cut-offs values; if these two
studies are excluded, the estimated value is 1.47 ng/mL.
Data uniformization
Data uniformization is required for the meta-analysis of Cohen’s d effect size. In the study of
Sachse et al. [18], PCT values were reported as the median by different post-burn time intervals
(6 distinct intervals) for septic and non-septic groups; the average and the standard deviation
of PCT values were deduced assuming the normal behavior of PCT values (mean ¼
P
mediani
6
;
std ¼
ffiffiffi
n
p
stdmedian).
In Neely et al. [20] and Lavrentieva et al. [27] (both in sepsis and non-sepsis groups PCT
standard deviation by each group was obtained using the inter-quartile distance and assuming
the normal behavior of PCT values (interquartile range = 1.35σ). In Cakir Madenci et al. paper
[22], it was calculated using the quantiles 2.5% and 97.5% and the normality assumption
(x0.975-x0.025 = 3.92σ).
Fig 1. Flow chart for the selection process of studies for evaluation of procalcitonin (PCT) in sepsis diagnosis.
doi:10.1371/journal.pone.0168475.g001
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In Bargues et al. [16], log values were transformed and combined in order to obtain the
PCT average and standard deviation, and the subgroup values are combined to obtain the
pooled standard deviation and the weight average. Lavrentieva et al. [19] combined subgroup
values to obtain the pooled standard deviation and the weight average of PCT for non-sepsis
groups.
As Barati et al. [15], Bognar et al. [29] and Mokline et al. [21] did not present AUC standard
error, the estimates for standard error were computed using the Hanley and McNeil procedure
[30]. Paratz et al. [24] reported the PCT discriminative power as not significant with AUC =
0.38 (95% Confidence Interval (95% CI) 0.29 to 0.46). However, if the classifier was negated
on every instance, the true positive (TP) classifications become false negative and the false pos-
itive become true negative (TN), and we obtain AUC = 0.62 and, for the cut-off chosen by the
authors (1.4 ng/mL), the corresponding sensitivity is 80 and the specificity is 36.
In Lavrentieva et al. [27], Kim et al. [25], Cakir et al. [22], Seoane et al. [23] and Paratz et al.
[24], the standard error is estimated from AUC confidence interval (SE = (UB-LB) / 3.92).
Table 1 presents the estimate AUC and the corresponding standard error for each study.
To evaluate PCT as a diagnostic marker for sepsis, there are several studies based on time-
points with repeated measures and others with independent ones and, in this context, the
results were used as independent.
Meta-analysis
For all effect sizes under analysis, the studies show significant heterogeneity (p<0.01, I2>50%),
thus a random-effects model for meta-analysis was used.
AUC plays a central role in evaluating diagnostic ability of tests, in particular of PCT bio-
marker. Ten studies under analysis present the PCT AUC estimate value and the first four
Table 1. Area under the curve (AUC) and the corresponding standard error (SE) for each study evaluating the ablity of procalcitonin (PCT) as a bio-
marker, and the overall estimate using random effects model.
Study Cut-off (ng/mL) Time points N ROC AUC SE 95%CI Tp Fp Fn Tn
Sachse, 1999 ( N/A N/A 19 N/A N/A N/A N/A N/A N/A N/A
von Heimburg, 1998 3 27 27 N/A N/A N/A 2 0 16 9
Neely, 2004 5 62 20 N/A N/A N/A 11 12 15 24
Abdel-Hafez 2007 N/A N/A 42 N/A N/A N/A N/A N/A N/A N/A
Bargues, 2007 0.534 359 25 0.66 0.04 0.59–0.72 39 29 53 237
Lavrentieva, 2007 1.5 934 43 0.98 0.03 0.91–1.04 93 72 21 748
Barati, 2008 0.5 60 60 0.97 0.02 0.93–1.01 30 3 0 27
Bognar, 2010 2 196 28 0.77 0.03 0.70–0.83 73 32 11 78
Lavrentieva, 2012 1.5 139 145 0.97 0.01 0.94–0.99 64 5 9 67
Kim, 2012 2 175 175 0.84 0.03 0.79–0.90 72 15 21 67
Cakir Madenci, 2013 0.759 611 37 0.85 0.02 0.81–0.88 181 79 59 292
Seoane, 2014 1.7 34 34 0.55 0.11 0.33–0.77 4 0 12 18
Paratz, 2014 1.4 345 54 0.62 0.04 0.54–0.70 38 190 10 106
Mokline, 2015 0.69 121 121 0.93 0.03 0.87–0.98 39 12 5 65
Total (AUC random effects) 0.83 0.04 0.76–0.90
Q 182.0
p-value <0.001
I2 95%
N—total number of individuals; ROC AUC—receiver operating characteristic area under the curve; 95%CI—95% confidence interval; Fn—false negative;
Fp—false positive; N/A–not available; Tn—true negative; Tp—true positive.
doi:10.1371/journal.pone.0168475.t001
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studies reported in Table 1 do not present AUC values. Table 1 presents the overall estimated
AUC for PCT for sepsis diagnosis, where the pooled estimate is 0.83 (95% CI = 0.76 to 0.90).
PCT diagnosis ability is significant (AUC>0.5) and the effect size is strong.
The publication bias associated with the AUC on diagnostic sepsis effect was analysed by
the funnel plot and the Egger test. The result of Egger’s test was significant (p <0.001), which
is manisfested in funnel plot asymmetry (Fig 3). It is of note that the studies appearing to have
higher effect in the publication bias are those which had lower AUC values.
To find out sources of heterogeneity, a subgroup analysis was done, using the random effect
model, according to different criteria used for sepsis determination in the works of the sample,
namely clinical evaluation, Baltimore Sepsis Scale, American College of Chest Physicians/Soci-
ety of Critical Care Medicine (ACCP/SCCM) definition and the more recent and specific one
from the American Burn Association (ABA) (Table 2). In order to reduce subjectivity using
standardized concepts, this analysis included just the works explicitly employing the ACCP/
CSCCM or the ABA definition. For the former subgroup, the AUC was 0.87 (95% CI = 0.63 to
1.0) and for the later it was 0.87 (95% CI = 0.71 to 0.90).
We also conducted another subgroup analysis, excluding retrospective studies [31,32],
achieved an AUC of 0.86 (95% CI = 0.78 to 0.93).
Similarly to the analysis presented by Ren et al. [13], the summary receiver operating char-
acteristic (SROC) for PCT in sepsis diagnosis was obtained including all the studies considered
(four additional studies to those included in Ren et al.). Data reported for SROC estimation by
these authors have, however, some differences in comparison to the data used in the present
work (Table 1). When the study reported the use of several time-points, the total of time-points
Fig 2. Bubble plot of cut-off for procalcitonin (PCT) in sepsis diagnosis for 12 studies organized by year. Bubble size corresponds to the number of
time-points.
doi:10.1371/journal.pone.0168475.g002
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was used as sample size instead of the total number of individuals [16,19,21,22,24,29]. More-
over, as the revision from Bognar et al. [29] was developed including only septic patients, this
feature could add some additional bias.
Fig 4 plots the sensitivity vs the false positive rate of all studies (using the values indicated in
Table 1), presenting the SROC and achieving an overall AUC of 0.87 (SE = 0.04). The results
produced by this method are in accordance with those obtained directly by the DerSimonian-
Laird method (Table 1). The pooled sensitivity and specificity are 0.77 (95% CI = 0.72 to 0.80)
and 0.65 (95% CI = 0.62 to 0.69), respectively.
PCT mean values for sepsis and non-sepsis groups for eleven individual studies are pre-
sented in Table 3. All the studies presenting the values by groups were considered. Due to the
Fig 3. Funnel plot of the AUC on diagnostic sepsis effect
doi:10.1371/journal.pone.0168475.g003
Table 2. Study characterization by sepsis criteria employed, type of design and population age.
Study Sepsis Criteria Design Type Population Age
von Heimburg, 1998 BSS Prospective Adult
Sasche, 1999 Clinical Retrospective Mixed
Neely, 2004 Clinical Prospective Paediatric
Abdel-Hafez, 2007 Clinical Prospective Paediatric
Bargues, 2007 ACCP/SCCM Prospective Adult
Lavrentieva, 2007 ACCP/SCCM Prospective Adult
Barati, 2008 ACCP/SCCM Prospective Adult
Bognar, 2010 ABA Prospective Adult
Lavrentieva, 2012 ABA Prospective Adult
Kim, 2012 Clinical Prospective Adult
Cakir Madenci, 2013 ABA Prospective Adult
Seoane, 2014 ACCP/SCCM Retrospective Adult
Paratz, 2014 ABA Prospective Adult
Mokline, 2015 ACCP/SCCM Prospective Adult
doi:10.1371/journal.pone.0168475.t002
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significant heterogeneity, the overall mean estimate was obtained assuming the random effects
model: 46.8 ng/mL (95%CI = 2.5 to 91.1) for sepsis group and 0.9 ng/mL (95%CI = 0.1 to 1.6)
for non-sepsis group. This analysis is useful to evaluate the strength of the PCT concentration
for each group, and a statistically significant mean difference was observed between sepsis and
non-sepsis groups.
In the sepsis group, there are three studies with very high PCT concentration (von Heim-
burg et al. [17], Bargues et al. [16], Abdel-Hafez et al. [26]) (>45 ng/mL); excluding these stud-
ies, an overall PCT mean value of 6.4 ng/mL (95%CI = 3.8 to 9.0) was obtained for the sepsis
group and of 0.6 ng/mL (95%CI 0.2 to 0.9) for the non-sepsis group. The mean results are
robust after the exclusion of these three studies, which perhaps shall be considered as outliers
related to different dosing methodology.
Fig 5 shows the mean difference effect sizes (sepsis and non-sepsis group on PCT concen-
tration) for the eleven studies. Two of these studies (Abdel-Hafez et al. [26], Bargues et al.
[16]) reported a much higher difference between groups than the difference observed in the
other studies. Due to this clear heterogeneity, a subgroup analysis was performed. Inside
both subgroups, the heterogeneity is also significant (p<0.001, Cochrane Q test), justifying
Fig 4. Summary receiver operating characteristic (SROC) curve of procalcitonin (PCT) for the diagnosis of sepsis in burn patients.
doi:10.1371/journal.pone.0168475.g004
Use of Procalcitonin for Diagnosis of Sepsis in Burn Patients
PLOS ONE | DOI:10.1371/journal.pone.0168475 December 22, 2016 8 / 16
28
therefore the use of random effects models. The overall sepsis effect is significant (95%CI = 1.1
to 3.2 with overall estimate of 2.1 ng/mL). Including only the low difference group, the overall
effect remains significant, but the effect strength is lower (0.9 ng/mL with 95%CI = 0.2 to 1.5),
as expected.
Sensitivity analysis by excluding one study at each turn and pooling results from the
remainder further confirmed the robustness of the findings, confirming the significance of the
sepsis effect on PCT concentration (Table 4).
The result of Egger’s test was not significant (p = 0.194). Thus the publication bias associ-
ated to the meta-analysis of difference of PCT levels between sepsis and non-sepsis groups
seems to be not relevant. However, the oldest studies included in the meta-analysis of sepsis
effect (Fig 5) caused (non-significant) funnel plot asymmetry (Fig 6). Doing again a subgroup
analysis based on the used sepsis definition, the resulting values for Cohen’s d were 3.69 (95%
CI = 0.45 to 6.92) when ACCP/SCCM classification was employed; 0.64 (95% CI = 0.02 to
1.26) according to ABA classification and 3.38 for the rest (95% CI = 0.90 to 5.87).
Discussion
Burns represent a public health problem and are an important cause of mortality and morbid-
ity around the World. According to the World Health Organization (WHO), it is estimated
that 265 000 deaths occur every year from fire-related burn injuries. Most of these injuries
occur in low- and middle-income countries and almost half of these cases are registered in the
South-East Asia Region. Moreover, burns are one of the major causes of disability-adjusted life
years (DALYs) lost in these countries. It was estimated in 2004 that nearly 11 million people
worldwide were burned severely enough to require medical support. Burns also significantly
impact the healthcare-related costs, in particular concerning prolonged hospitalization peri-
ods, burn management, and care for disfigurement and emotional trauma [33].
Table 3. Procalcitonin (PCT) mean values and the corresponding standard error (SE) for each study, and the overall estimate using random effects
model estimated by group (sepsis and non-sepsis group).
Sepsis group Non-sepsis group
Study and year Mean SE N Mean SE N
Sachse, 1999 3.9 11.7 9 0.4 0.4 10
von Heimburg, 1998 49.8 76.9 18 2.3 3.8 9
Neely, 2004 6.7 20.4 36 2.1 3.2 26
Abdel-Hafez, 2007 369.1 11.4 20 47.4 10.7 22
Bargues, 2007 45.5 10.9 92 2.8 1.1 267
Lavrentieva, 2007 11.8 15.8 114 0.6 0.4 820
Barati, 2008 8.5 7.8 30 0.5 1.0 30
Lavrentieva, 2012 7.2 24.1 86 0.7 2.8 53
Cakir Madenci, 2013 2.0 22.0 240 0.3 2.7 371
Seoane, 2014 3.0 5.4 16 0.6 0.3 18
Mokline, 2015 7.3 7.0 44 0.9 0.5 77
Total (random effects) 46.8 22.6 0.9 0.4
Q 19649 24
p-value <0.001 0.004
I2 100% 63%
95%CI 2.49–91.05 0.10–1.61
N—total number of individuals; 95%CI—95% confidence interval; SE—standard error.
doi:10.1371/journal.pone.0168475.t003
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Severe burn injuries that affect all body systems and their regulatory pathways may be
considered as a paradigm of polytrauma. Tissue injury, coupled with the release of multiple
local and systemic mediators of inflammation, leads to an increase in vascular permeability,
Fig 5. Forest plot for sepsis effect on procalcitonin (PCT) concentration. The estimated overall effect size and confidence
interval (Cohen’s d, displayed as a diamond) and individual effect sizes (Cohen’s d, displayed as a rectangle) are shown.
doi:10.1371/journal.pone.0168475.g005
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resulting in marked hydroelectrolytic and cardiovascular alterations [34]. These alterations
rapidly evolve to a state of hypovolemic shock, with loss of water, proteins and electrolytes,
which is usually fatal if not adequately treated. In the past, shock was indeed the first cause of
death in these patients. However, the great advances observed in intensive care have reversed
this situation and today this initial acute phase of hypovolemia is overcome with success in the
majority of the cases [35]. Nowadays, sepsis has become the major cause of death in burn
patients, occurring generally in a late post-traumatic period [35,36].
Considering the patients with suspected infection, septic patients have obviously the worst
outcomes [37]. These outcomes may be highly improved, if the appropriate antibiotics are
administered early and timely [38]. The use of reliable biomarkers that early identify a septic
process may have a great importance to help the physicians to select patients for prompt
Table 4. Sensitivity analysis of overall sepsis effect (Cohen’s d) in procalcitonin (PCT) levels in burn
patients.
Excluded study Pooled d 95%CI
Sachse, 1999 2.317 1.170–3.464
von Heimburg, 1998 2.290 1.139–3.442
Neely, 2004 2.365 1.190–3.539
Abdel-Hafez 2007 1.520 0.480–2.559
Bargues, 2007 1.182 0.447–1.917
Lavrentieva, 2007 2.279 0.992–3.566
Barati, 2008 2.237 1.067–3.406
Lavrentieva, 2012 2.404 1.183–3.624
Cakir Madenci, 2013 2.467 1.204–3.730
Seoane, 2014 2.309 1.150–3.468
Mokline, 2015 2.255 1.057–3.453
95%CI–95% confidence interval.
doi:10.1371/journal.pone.0168475.t004
Fig 6. Funnel plot of the difference of procalcitonin (PCT) levels between sepsis and non-sepsis groups
(Cohen’s d effect sizes).
doi:10.1371/journal.pone.0168475.g006
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antibiotic therapy, particularly when clinical signs are absent or unclear. On the other hand, if
the biomarker levels are under the cut-off values defined for septic processes, this information
may suggest that an inflammatory non-infectious process is occurring. So, these tests are also
useful to avoid unnecessary antibiotherapy, which may result in toxicity and development of
antimicrobial resistance.
PCT is a 116-aminoacid prohormone of calcitonin, which is mainly produced by the C-
cells of thyroid gland and participates in calcium metabolism [39]. PCT is also synthesised in
other tissues, including liver, kidney, lung and adipose tissue, in response to endotoxins, cyto-
kines and other mediators released during the infection period [40]. PCT blood levels are
barely detectable in healthy individuals. However, in the presence of systemic bacterial infec-
tion or, in a lower scale, fungal infection, its levels suddenly undergo a dramatic increase, fol-
lowing the infection course and then quickly subside after the control of the septic process.
There is strong clinical evidence that PCT allows differentiation between non-infectious sys-
temic inflammatory response and microbiological infection by bacteria or fungi and several
studies confirm its utility as a reliable means to guide antibiotic use in community-acquired
pneumonia and sepsis in intensive care patients [11,12,41–46]. Some studies also suggest its
usefulness in the diagnosis and prognosis of sepsis in burns patients [17–19,27,47] [S3 File],
though some controversy still persists [16,28,48]. PCT is currently one of the most investigated
biomarkers and has already been integrated in treatment algorithms for patients with lower
respiratory airways infections [12] and for ICU patients [28].
The main finding of this meta-analysis is that most of the included studies indicate that
PCT can be a simple and very useful biomarker for the early identification of sepsis in burn
patients, when used in combination with relevant clinical examination and other biomarkers
available (e.g. leukocytosis, C-reactive protein, MR-pro-adrenomedullin) [18,49–52]. In fact,
the pooled information resulting from this work suggests the feasibility of PCT quantification
in these patients, showing that an average cut-off of 1.5 ng/mL is a strong indicator for sepsis
suspicion and therefore for the initiation of antibiotherapy.
In addition, this work demonstrated that overall pooled area under the SROC curve was
0.87, with a sensitivity of 0.77 and a specificity of 0.65. The area under the SROC curve and the
sensitivity are in agreement with the results published by Ren et al. [13], which reported that
the area under the SROC curve was 0.92, with a sensitivity of 0.74. On the other hand, the spec-
ificity reported in this work was lower (0.65 vs 0.88) and the publication bias was significant.
Thus, the inclusion of four additional studies in this meta-analysis, including two pediatric
studies, contribute to support and strengthen the evidence supporting the interest of PCT lev-
els as a biomarker for the early diagnosis of sepsis in burn patients. The sensitivity analysis,
performed by excluding one study at each turn, also confirmed the sepsis effect on PCT con-
centration in burn patients. Nevertheless, the inclusion of these pediatric studies may explain
the lower specificity and the higher heterogeneity reported in our work, as a population with
different physiologic characteristics was considered in the analysis.
This work also included a sub-group analysis, comparing sepsis and non-sepsis groups of
the studies included. This analysis revealed that sepsis group showed a statistical significant
increase in the PCT mean values, in comparison with non-sepsis group. It also indicated that
both groups were highly heterogeneous, though this parameter was higher in the sepsis group.
Moreover, no significant publication bias was registered between sepsis and non-sepsis groups.
The increase of PCT levels in patients diagnosed with sepsis corroborates the potential useful-
ness of this prohormone in burn patients with sepsis.
However, some studies reported that PCT levels can temporarily increase in some patients
postoperatively, even in the absence of infection [41]. This increase is minor and rapidly sub-
sides, but it must obviously be taken into account. In addition, some previous studies did not
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confirm that PCT levels may be helpful for the diagnosis of sepsis in burn patients [23,24,48],
which may result from several factors, such as a small sample size, heterogeneity among
patients included in the analysis, different criteria for sepsis diagnosis and different timings of
sampling [25].
This work has some limitations that must be considered when interpreting the results. Only
12 studies were available for meta-analysis and the number of patients included was in general
small and heterogeneous between the different studies. The cut-offs values, which ranged from
0.5 to 5 ng/mL, and the methods used to quantify the PCT concentration also diverged in
these studies. The high heterogeneity of the studies is also a factor that may rise questions
about the utility of this biomarker. The inclusion of two pediatric studies, as referred, may had
a significant impact in this parameter. Another limitation relies on the origin of the data
included in the analysis. In fact, only published studies written in English were considered,
which may imply the exclusion of significant and important data obtained in unpublished
studies and studies written in other languages.
Based on these studies, in the authors’ opinion, PCT levels should be determined daily in
burn patients at high risk of infection (large total body surface area [TBSA] burns, mechanical
ventilation, comorbidities, etc.), and at least twice a week for the rest of the burn patients. How-
ever, further studies with significant number of patients and planned to reduce the variability of
cut-off values, number of timepoints and methods to quantify PCT levels should be conducted,
to better evaluate the interest of PCT as a biomarker for early diagnosis of sepsis in burn
patients. Studies combining the determination of PCT levels and the evaluation of other poten-
tial biomarkers or other clinical evidence should also be done, as generally the single determina-
tion of one biomarker is not sufficient to predict or early diagnose the septic process.
Conclusion
This meta–analysis showed PCT may be considered as a biomarker with a strong diagnostic abil-
ity to discriminate between the septic and the non-septic burn patients. The overall sepsis effect
is significant and the overall association between PCT levels and the occurrence of mortality is
also significant. This work clearly encourages the serial and frequent measurement of PCT levels
in clinical practice for the management of burn patients, in order to timely identify the suscepti-
bility to sepsis and to initiate the antimicrobial therapy, improving the patients’ outcomes
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a b s t r a c t
Background: The gold standard for sepsis diagnosis in burn patient still relies on
microbiological cultures, which take 48–72h to provide results, delaying the start of
antimicrobial therapy. Thus, biomarkers allowing an earlier sepsis diagnosis in burn patients
are needed.
Methods: This retrospective observational study included 150 burn patients with total burned
surface area 15%. Clinical diagnosis of sepsis among these patients was done according to
the American Burn Association criteria. Biomarker (procalcitonin, white blood cells and
platelet countings, prothrombinemia, D-dimers, C-reactive protein, blood lactate and
temperature) values were available for 48 patients without sepsis (2767 timepoints) and
102 patients with sepsis (652 timepoints). Quantitative variables were compared with Mann–
Whitney tests and qualitative variables were compared with Pearson chi-square test. Effect
size was measured by the probability of superiority. Receiver operating characteristic (ROC)
curves evaluate capacity for sepsis diagnosis. Sensitivity, specificity, positive and negative
predictive values were calculated for some cut-off values, including the best cut-off defined
by the maximum of Youden index.
Results: Statistically significant differences between the groups of septic and non-septic
patients, with medium to large effect size, were detected for all the biomarkers considered,
except temperature. PCT was the biomarker with the largest AUC and effect size (AUC=0.71).
Analysis of the PCT ROC curve showed that 0.5ng/mL cut-off presented highest sensitivity
and lowest specificity, whereas 1.5ng/mL cut-off was associated with lowest sensitivity and
highest specificity.
Conclusion: Procalcitonin showed to be the best of the biomarkers studied for an early
diagnosis of sepsis. Its use should be considered in antimicrobial stewardship programs in
Burn Units.
© 2017 Elsevier Ltd and ISBI. All rights reserved.
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1. Introduction
Severe burns are considered a relevant public health issue as
they affect patients’ physical and mental health, having an
important negative impact on their quality of life. The
management of burns also represent significant costs for
the healthcare sector, in particular due to prolonged hospitali-
zation periods and care of disfiguring injuries [1]. Sepsis is a
comorbidity commonly observed in severe burn patients and
is the major cause of their death [2,3]. In fact, severe burns
increase the susceptibility to sepsis, as they propitiate the
development of infections, due to several factors including
skin injury, necrosis, use of catheters and other invasive
devices, and exposure to nosocomial flora [4,5]. According to a
recent review the literature, the prevalence of sepsis in burn
patients ranges from 8% to 42% and the associated mortality
rate varies form 28% to 65%. [6], its values being naturally
related to the severity of the process [7] and the promptitude of
the diagnosis and the beginning of therapy, as in other causes
of initial injury [8,9]. The arising of multidrug resistant
microorganisms in the last years has contributed to an even
worst scenario [10]. Thus, it is of critical importance to timely
diagnose and treat septic episodes in these patients. However,
the identification of sepsis causative microorganisms takes 2–
4 days, which may delay the start of the specific antimicrobial
treatment [11]. On the other hand, the clinical and laboratorial
findings of sepsis are also present in other clinical conditions
with a systemic inflammatory response (trauma, anaphylaxis,
pancreatitis, hemorrhage, etc.) [12] which complicates the
differential diagnosis [13]. In this context, the use of
biomarkers has been advocated to improve clinicians’ ability
to detect sepsis early in order to start a timely and adequate
antimicrobial therapy.
The ideal biomarker should be suitable for the early
diagnosis of sepsis (either as a part of a routine screening
exam or at the first sign of a suspect clinical sign); should
follow the course of the infection and reflect the efficacy of the
therapy, allowing for its monitoring and suspension; should be
safe and easy to measure; should be cost effective to follow-up
and consistent across gender and ethnic groups. Such a
biomarker has not yet been discovered, but several ones are
already in use and coupled with a sound clinical examination
may in fact support clinicians on the decision to start, and stop,
antimicrobial therapy.
Among over 170 biomarkers described in the literature in
the last decades [14], procalcitonin (PCT) has emerged, not
without some controversy [15], as one of the most useful and
reliable [16–28]. PCT is the hormonally inactive 116-amino
acid precursor of calcitonin, a hormone that is mainly
secreted by the C-cells of thyroid gland that are involved in
calcium metabolism [29]. PCT can also be synthesized in
extrathyroid tissues in response to endotoxins and proin-
flammatory cytokines release during and infection, but also
in non-infectious conditions with systemic inflammation
(e.g. multiple trauma, drug adverse reactions, cardiogenic
shock, etc.). PCT serum levels are very low in healthy
individuals but these levels markedly increase up to 1000-
fold within 2–4h of sepsis onset [30], and then rapidly decline
after successful antimicrobial therapy. Scientific evidence
corroborated that this peptide has a good capacity to
distinguish between systemic non-infectious inflammatory
response and septic conditions caused by bacteria or fungi in
patients with community-acquired pneumonia [16,17] and in
septic patients in intensive care units [18,19,29]. Several
reports also support the utility of PCT for the diagnosis of
sepsis in burn patients [21–28], though other authors
question this evidence [31,32]. The current study aims to
contribute for the determination of the potential utility of
PCT as a biomarker for the early diagnosis of sepsis in burn
patients. For such a purpose, PCT levels were assessed in
different periods during hospitalization of burn patients in a
specialized burn care unit and its discriminatory power was
compared against other commonly used biomarkers.
2. Material and methods
2.1. Patients
The sample under analysis was composed by burn patients
with partial, deep partial and/or full thickness burns
comprising 15% or more of total burn surface area (TBSA),
admitted consecutively from January 2011 to December
2014 at Coimbra Burns Unit (CBU), a department of Coimbra
Hospital and University Centre (CHUC), Portugal. Burn
patient data were obtained retrospectively by consulting
the hospital database.
The diagnosis of sepsis was based on the American Burn
Society (ABA) criteria [33]: a clinical suspicion of infection
coupled with the presence of the presence of three or more of
the following parameters: temperature >39C or <36.5C;
tachycardia >110 beats per min; tachypnea >25 breaths per
minute or minute ventilation >12L/min; thrombocytopenia
<100,000/mL; hyperglycemia (untreated plasma glucose
>200mg/dL or intravenous glucose use >7U/h over 24h;
enteral feeding intolerance: abdominal distension or gastric
residuals more than two times feeding rate or diarrhea
>2,500mL/min.
A timepoint was defined as day of analysis results; each
patient had several timepoints. The total timepoints were
distributed in two groups, sepsis and non-sepsis, according to
the ABA criteria above. In order to avoid bias, subjectivity and
trying to give more strength to the analysis, only microbiolog-
ical blood tests were considered, independently of the known
or suspected primary focus of the septic episode. From all
patients of the sample, at least 3 (three) blood samples per
week, in different days, were collected for PCT assessment.
When there was a clinical diagnosis of sepsis according to ABA
criteria, PCT was evaluated daily. In the cases where for the
same patient, by any reason, there were two assessments of
PCT in the same day, the highest value was taken for study
purpose.
2.2. Laboratory measurements
At each time point, the following data were collected from the
database: PCT, white blood cell counting, platelet counting,
prothrombinemia, D-dimers, C-reactive protein (CRP), blood
lactate and temperature.
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PCT was measured with TRACE (time-resolved amplified
cryptate emission) technology (Kryptor
1
PCT; Brahms AG;
Hennigsdorf, Germany). White blood cells and platelets
automated counting was performed by flow cytometry
(UniCel DxH
1
800 Coulter Cellular Analysis System; Beckman
Coulter Ireland Inc.; Galway, Ireland). Prothrombin and D-
dimers were quantified by automated latex enhanced
immunoassay in human citrated plasma on the (ACL TOP
1
Family Systems, HemosIL D-Dimer HS 500; Instrumentation
Laboratory SpA; Milano, Italy). CRP concentrations were
quantitatively determined by the immunoturbidimetric
method (Architect
1
c8000 System; Abbott; Wiesbaden,
Germany).
2.3. Statistical analysis
Data were summarized by location measures (mean, median,
minimum, maximum, percentiles) and dispersion measures
(standard error [SE] and range).
The variables under study presented a non-Gaussian
distribution. Under a nonparametric approach, the quantita-
tive variables were analyzed with Mann–Whitney U test and
qualitative variables were analyzed with Pearson chi-square
test. To measure the effect size the probability of superiority
(PS) was used. PS ranges from 0 to 1 and PS=0.5 states that there
are no differences between the groups, meanwhile PS=0 or
PS=1 state the maximum effect.
Receiver operating characteristic (ROC) curves, in partic-
ular the area under the curve (AUC), were performed to
evaluate the selected biomarkers potential for sepsis
diagnosis. Sensitivity, specificity, positive (PPV) and negative
predictive values (NPV) were calculated for some cut-off
values. The most accurate cut-off value was calculated by the
Youden Index (J=sensitivity+specificity1) [34].
Statistical analysis was performed with SPSS© 23.0 IBM© for
Windows© (IBM Corp., Armonk, NY, USA). The statistical
hypothesis tests with p-value <0.05 were considered signifi-
cant. The confidence intervals are reported with 95% confi-
dence level.
3. Results
This retrospective study included 150 patients with a total of
3,419 time points (2,767 time points without sepsis and 652
with sepsis). Table 1 presents the characteristics of study
population, dividing the patients in two groups: sepsis group
(patients with at least one time point with sepsis during
hospitalization, n=102), and non-sepsis group (patients
without any time point identified by sepsis during hospitali-
zation, n=48). The sepsis and non-sepsis groups presented
gender and age homogeneity. All other variables showed
statistically significant differences between both groups.
Following the works of Lavrentieva et al. [26], a sub-analysis
was done, reporting the median values of some biomarkers,
sorting out the patients with less or more than 60% TBSA
(Table 2). Patients with TBSA 60% presented significantly
higher concentrations of PCT and D-dimers than patients with
TBSA <60%, whereas prothrombin levels were higher in
patients with TBSA <60%. Regarding the other biomarkers,
no significant differences were observed between groups.
Although significant, the effect sizes for all biomarkers and
both TBSA groups were small.
In order to study the diagnostic power of the different
biomarkers used at Coimbra Burns Unit, we compared
biomarkers between septic and non-septic patients (Table 3).
There were significant differences between the two groups of
patients, with medium to large size effects, except for
temperature. PCT was found to be the biomarker with the
strongest effect size (0.28, a large effect size). Fig. 1 presents the
median PCT values registered in burn patients with or without
sepsis.
The areas under the ROC curves (AUC) were calculated to
evaluate the biomarker power to differentiate a sepsis from a
non-sepsis situation (Table 4). Temperature showed a low, not
significant, accuracy for sepsis diagnosis. All the other
biomarkers presented statistical significance (as the confi-
dence intervals did not overlap) and accuracy (AUC different
from 0.5; p-value<0.05).
Table 1 – Characteristics of the study population.
Characteristics Sepsisb Non sepsis p-Value
Number of patients 102 48
Gender (male/female) 57/45 29/19 0.600
Age (years)a 60.0 (41.5–79.0) 57.5 (40.8–64.8) 0.144
Burn degree (2nd/2nd & 3rd/3rd) 9/75/18 15/27/6 0.002*
ABSI score 8.0 (7.5–10.0) 6.0 (5.3–8.0) 0.000*
TBSA (%)a 29.0 (20.0–38.8) 19.0 (16.0–25.0) 0.000*
Inhalation injury (yes/no) 42/60 6/42 0.000*
Mechanical ventilation (yes/no) 54/47 8/40 0.000*
Antimicrobial therapy (days)a 16.0 (5.5–28.0) 0(0–6.0) 0.000*
Length of stay (days)a 33.0 (20.5–53.5) 17.0 (12.0–21.0) 0.000*
Mortality (yes/no) 33/69 5/43 0.004*
Surgery (number of interventions)a 4.0 (2.0–5.0) 1.0(0–2.0) 0.000*
a Values are median (Q1–Q3).
b At least one time point identified by sepsis during hospitalization.
* p-Values<0.05.
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Using all timepoints and assuming that PCT was the
biomarker with the greatest AUC (Table 4 and Fig. 2) and that
PCT demonstrated a large effect size with AUC >0.71 (according
to Rice and Harris [35]), we analyzed the ROC curve of PCT to
assess the most suitable cut-off for the diagnosis of sepsis in
burn patients (Table 5). The cut-off of 0.5ng/mL presented the
highest sensitivity and the lowest specificity, whereas 1.5 was
least sensitive and the most specific.
4. Discussion
We analyzed some putative biomarkers for early sepsis
diagnosis in groups of septic and non-septic burn patients
and concluded that PCT was the most reliable biomarker for
sepsis diagnosis, in comparison to the other studied biomark-
ers (white cells and platelets counting, prothrombin, D-
dimers, CRP, blood lactate and temperature). To our knowl-
edge, this is the largest study of the use of PCT for sepsis
diagnosis in burn patients, which allows a strong statistical
analysis.
Currently, the leading cause of mortality of burn patients
is sepsis. To prevent this mortality, it is crucial to start an
early and adequate antimicrobial therapy because any delay
increases the risk of death. However, it is not easy to
correctly identify the sepsis onset in burn patients only based
on clinical criteria, even when adjusted for this group of
patients [23], because large burns induce an overwhelming
systemic inflammatory response that mimics a septic
episode. On the other hand, the superfluous prescription
of antimicrobials must be avoided in order to decrease
antimicrobial pressure and emergence of antimicrobial
resistance. Attending that the gold standard for sepsis
diagnosis is still the identification of microorganisms in
the bloodstream and that in most health facilities blood
cultures results take 48–72h from the sampling, the use of
biomarkers, alone [11] or in combination [36], has been
regarded as an extremely important strategy to support
clinician’s decision to start antimicrobial therapy.
The use of PCT for sepsis diagnosis in burn patients has
been first advocated by von Heimburg in 1998 [21], and
supported later by several authors [22–28], but there are also
some contradictory reports [31]. Our results corroborate the
usefulness of PCT assessments in burn patients to early
diagnosis sepsis and start antimicrobial therapy. Moreover,
sample stratification by TBSA under and above 60% shows
small, but significant, differences for PCT, prothrombin and D-
dimers. P-value was higher for PCT suggesting a lesser
correlation with burn size.
All the studied biomarkers, except temperature, showed
statistically significant differences between septic and non-
septic patients, but PCT stands out with the largest size effect.
This superior diagnostic power is corroborated by the analysis
of ROC curves, as PCT had the largest AUC.
Table 2 – Biomarkers levels according to TBSA.
Biomarker TBSA<60% TBSA60% p-Value PS
Nr. of timepoints Median (Q1–Q3) Nr. of timepoints Median (Q1–Q3)
Procalcitonin (ng/mL) 3056 0.39 (0.16–1.17) 286 0.62 (0.17–1.83) 0.036* 0.47
White cells (109/L) 3542 11,400 (8800–15,200) 305 13,200 (9550–19,050) 0.087 0.47
Platelets (109/L) 3539 279 (162–415) 305 304 (180–403) 0.442 0.49
Prothrombinemia (%) 3353 70 (61–78) 292 64 (58–71) 0.000* 0.40
D-dimers (mg/mL UEF) 2768 1.39 (0.93–2.16) 249 2.18 (1.12–4.06) 0.010* 0.46
C-react. prot. (mg/mL) 480 13.87 (8.84–20.65) 29 15.08 (8.58–25.96) 0.565 0.47
Lactate (mmol/L) 803 1.49 (1.01–2.06) 98 1.40 (1.06–2.11) 0.526 0.48
Temperature (C) 4063 37.6 (37.0–38.3) 311 38.1 (37.1–38.7) 0.271 0.48
PS: probability of superiority.
* Statistically significant (p<0.05).
Table 3 – Biomarkers levels in septic and non-septic burn patients.
Biomarker Sepsis Non sepsis p-Value PS
Nr. of timepoints Median (Q1–Q3) Nr. of timepoints Median (Q1–Q3)
Procalcitonin 652 1.08 (0.40–3.94) 2767 0.32 (0.14–0.88) 0.000* 0.28
White cells 710 14.7 (11.5–19.6) 3218 10.9 (8.4–14.4) 0.000* 0.31
Platelets 709 182 (94–318) 3216 300 (189–421) 0.000* 0.33
Prothrombinemia 680 63 (54–70) 3044 70 (62–79) 0.000* 0.34
D-dimers 601 1.96 (124–371) 2487 1.31 (0.89–2.03) 0.000* 0.34
C-react. protein 102 16.47 (12.94–23.03) 407 13.14 (8.19–19.90) 0.000* 0.36
Lactate 294 1.80 (1.21–2.57) 607 1.35 (0.94–1.86) 0.000* 0.35
Temperature 730 37.5 (36.9–38.4) 3726 37.6 (37.0–38,3) 0.693 0.50
* Statistically significant (p<0.05).
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Due to the variability of patient’s characteristics and
comorbidities, burn size, surgical procedures, analytic devices
and other factors that may slightly influence PCT levels, a
unique and absolute value for its cut-off for sepsis diagnosis
cannot be definitively established, although several have been
proposed. However, most authors agree that PCT dynamics is
the most useful and reliable [37]. In this study sample, a PCT
cut-off of 0.5ng/mL demonstrated high sensitivity (0.71) but
low specificity (0.62), whereas 1.5ng/mL reached the highest
specificity (0.83) but at the cost of a low sensitivity (0.43). The
arbitrary choice of 1.0ng/mL for cut-off may be advised
attending to the better combination of sensitivity (0.52) and
specificity (0.77), having a PPV of 38% and a NPV of 86%.
However, the best approach may be to consider 0.5ng/mL as an
alert cut-off, which indicates the need of at least a daily
measurement to monitor PCT evolution, and 1,0 or 1,5ng/mL
for the onset of pre-emptive antimicrobial therapy, de-
escalating to the lower spectrum drug when antimicrobial
sensitivity test is available.
The use of PCT in combination with other laboratorial and
clinical sepsis biomarkers will certainly reinforce the diagnos-
tic power [36]. Unfortunately, recent and promising
Fig. 1 – Median procalcitonin (PCT) values observed in septic (Yes) and non-septic (No) burn patients. In the presence present of
sepsis, PCT levels are significantly higher.
Table 4 – Biomarkers AUCs for sepsis diagnosis in burn patients.
Biomarker AUC SE p-Value Asymptotic 95% confidence interval Timepoints
Lower bound Upper bound
Procalcitonin 0.717 0.011 0.000* 0.696 0.738 3419
White cells 0.686 0.012 0.000* 0.663 0.709 3928
Platelets 0.672 0.012 0.000* 0.648 0.696 3925
Prothrombinemia 0.661 0.011 0.000* 0.639 0.684 3724
D-dimers 0.664 0.012 0.000* 0.640 0.688 3088
C-reactive protein 0.636 0.028 0.000* 0.581 0.692 509
Lactate 0.649 0.020 0.000* 0.610 0.688 901
Temperature 0.505 0.013 0.693 0.480 0.529 4456
* Statistically significant (p<0.05).
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biomarkers, such as proadrenomedullin (MR-proADM) [38–40],
CD64 neutrophil expression [41,42], biphasic transmittance
waveform of activated partial thromboplastin [43,44], brain
natriuretic peptide [45,46], presepsin [47–49], or extravascular
ling water index [50] are not readily available in most of the
hospitals, are expensive or are not yet validated for use in burn
patients. Thus, in face of a suspected inflammatory systemic
response, the use of clinical and traditional laboratorial
biomarkers in combination with PCT [51,52], in a dynamic
approach [51] with serial sampling [30], may represent a good
alternative and strengthens the reliability of PCT diagnostic
capacity.
Notwithstanding our interesting findings, this study has
some limitations. Firstly, this is a retrospective and
monocentric study, though analyzing a relatively large sample
and a great number of time points with standard procedures
for collection and recording of data. By the other hand, the
methodology employed may raise some concern about
sampling bias because a number of consecutive timepoints
were included. However, as they were taken separately, the
timepoints of patients from sepsis and non-sepsis groups
being undoubtedly distinct can, at least in great part, avoid bias
suspicion.
One strength of the study is the use of well-defined and
internationally accepted criteria for clinical suspicion of sepsis
[33], allowing a sound statistical analysis. Similar studies
should be developed in other burn centers and new biomarkers
should also be assessed. Additionally, a well-designed
Fig. 2 – Receiver operating characteristic (ROC) curves for the biomarkers used for early diagnosis of sepsis in burn patients.
Procalcitonin (PCT) showed the largest area under the ROC curve (AUC).
Table 5 – Sensitivity and specificity of PCT cut-offs for the diagnosis of sepsis in burn patients.
Cut-off (ng/mL) Sensitivity Specificity Youden indexa PPV NPV
0.5 0.71 0.62 0.33 0.87 0.34
1.0 0.52 0.77 0.29 0.86 0.38
1.5 0.43 0.83 0.27 0.86 0.38
NPV: negative predictive value.
PPV: positive predictive value.
a Youden index (J=sensitivity+specificity1).
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international multicentric prospective study, comparing PCT
to other biomarkers, would certainly be very valuable for the
complete understanding its potential for the diagnosis of
sepsis in burn patients.
5. Conclusions
This study shows that PCT monitoring can help the early sepsis
diagnosis and support clinicians on the decision to start or stop
antimicrobial therapy in burn patients. Thus, as proposed by
Meisner [30] for ICU patients, PCT measurements in antimi-
crobial stewardship programs in Burn Units may as well be an
important tool to an early sepsis diagnosis and to potentially
reduce mortality, toxicity, antimicrobial resistance arousal
and financial burden.
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Abstract
Background: Due to greater infection susceptibility, sepsis is the main cause of death in burn patients. Quick
diagnosis and patient stratification, early and appropriated antimicrobial therapy, and focus control are crucial for
patients’ survival. On the other hand, superfluous extension of therapy is associated with adverse events and arousal
of microbial resistance. The use of biomarkers, necessarily coupled with close clinical examination, may predict
outcomes, stratifying patients who need more intensive care, and monitor the efficacy of antimicrobial therapy,
allowing faster de-escalation or stop, reducing the development of resistance and possibly the financial burden,
without increasing mortality. The aim of this work is to check the suitability of procalcitonin (PCT) to fulfill these
goals in a large sample of septic burn patients.
Methods: One hundred and one patients, with 15% or more of total body surface area (TBSA) burned, admitted
from January 2011 to December 2014 at Coimbra Burns Unit (CBU), in Portugal were included in the sample. All
patients had a diagnosis of sepsis, according to the American Burn Association (ABA) criteria. The sample was
factored by survival (68 survivors and 33 non-survivors). The maximum value of PCT in each day was used for
statistical analysis. Data were summarized by location measures (mean, median, minimum, maximum, quartiles) and
dispersion measures (standard error and range measures). Statistical analysis was performed with SPSS© 23.0 IBM©
for Windows©.
Results: There were statistically significant differences between PCT levels of patients from the survivor and non-
survivor groups during the first and the last weeks of hospitalization as well as during the first week after sepsis
suspicion, being slightly higher during this period. During the first 7 days of antimicrobial therapy, PCT was always
higher in the non-survivor, still without reaching statistical significance, but when the analysis was extended till the
15th day, PCT increased significantly, rapidly, and steadily, denouncing therapy failure.
Conclusion: Despite being not an ideal biomarker, PCT proved to have good prognostic power in septic burn
patients, paralleling the evolution of the infectious process and reflecting the efficacy of antimicrobial therapy, and
the inclusion of its serial dosing may be advised to reinforce antimicrobial stewardship programs at burn units;
meanwhile, more accurate approaches are not available.
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Background
Sepsis is still nowadays the main cause of death in burn
patients due to the impact of extensive burns in all
organ systems, affecting homeostatic mechanisms, and
to the greater susceptibility of this population to infec-
tion [1, 2], related to the loss of the cutaneous barrier,
immunosuppression, use of invasive devices, nosocomial
flora, etc. Survival is directly dependent on the institu-
tion of prompt and adequate antimicrobial therapy [3].
However, the gold standard for sepsis diagnosis still re-
lies on the identification of microorganisms in blood
cultures, which unfortunately are positive only in 20–
30% of all confirmed bloodstream infections, and their
results may take 48 to 72 h to reach the prescriber [4].
While more rapid methods of microbiological identifica-
tion, such as polymerase-chain reaction (PCR) [5],
matrix-assisted laser desorption ionization–time of
flight mass spectrometry (MALDI-TOF MS), gene ex-
pression profiling, aptamer panels, etc. [6], are not either
widely available or fully developed, the use of early em-
pirical often broad-spectrum antibiotic therapy is war-
ranted. This empirical strategy increases the likelihood
of cure of infection and survival but negatively impacts
in terms of microbiome, leading to the selection and
emergence of antimicrobial resistance. In this context,
biochemical biomarkers, namely procalcitonin (PCT)
alone [7, 8] or integrating a composite panel [9–12], and
always coupled with thorough clinical examination, may
be an important aid for the early suspicion of sepsis and
rapid institution of therapy, which is strongly associated
with improved outcomes [13, 14].
PCT is a 116-amino acid precursor of calcitonin,
which synthesis and secretion, encoded by first calci-
tonin gene (CALC-I gene), and normally restricted to
thyroid C cells and some neuroendrocrine cells of the
lungs and gut, is upregulated by the presence in the
blood of microbial toxins, necrotic body cells, and some
proinflammatory cytokines (IL-1, IL-6, TNF-α, etc.), in a
synergistic way, starting to be produced in great
amounts by many other nonendocrine types of cells, in-
cluding monocytes and adipocytes [15], reaching meas-
urable levels in 2–4 h after onset of the infectious
process, peaking at 24–30 h, and rapidly subsiding with
recovery. PCT increment is less pronounced with fungal
infection and is absent in viral disease, allegedly due to
inhibition of its secretion by some cytokines released as
a response to viral infection, like interferon-γ [16].
Besides its utility to help clinicians in the diagnosis of
sepsis [17] including patients admitted to burn units [18],
the magnitude and duration of PCT elevation seems to
correlate with injury severity and outcome, and there are
several published works analyzing its potential for the
prognosis and for the monitoring of antimicrobial therapy,
helping decisions on early antibiotic de-escalation or res-
cue therapy [19–21]. Most of these are focused in lower
respiratory tract infections and/or intensive care patients,
while papers on septic burn patients are scarce [22].
The purpose of this work is to evaluate the feasibility
of PCT use to predict the outcome and to monitor the
efficacy of antimicrobial therapy in a sample of severe
adult burn patients.
Methods
The sample under analysis was composed by 101 burn
patients, with 15% or more of total body surface area
(TBSA) burned, admitted from January 2011 to
Table 1 Patients’ characteristics
Characteristics Survivors Non-survivors p value
Number of patients 68 33
Age (years) 53.0 ± 2.4
(18–85)
70.5 ± 3.5
(28–90)
0.000*
Male, gender (%) 38 (55.9%) 19 (57.6%) 0.872
Burn degree (2nd/2nd and 3rd/3rd) 8/50/10 1/24/8 0.219
ABSI score 8.0 ± 0.2
(4–13)
10.4 ± 0.4
(8–17)
0.000*
TBSA burned (%) 28.2 ± 1.6
(14–75)
40.7 ± 3.6
(15–90)
0.000*
Inhalation injury (%) 45 (66.2%) 15 (45.5%) 0.047*
Mechanical ventilation (%) 36 (52.9%) 4 (12.1%) 0.000*
Days of mechanical ventilation 11.3 ± 2.3
(0–70)
22.4 ± 3.8
(0–76)
0.000*
Duration of sepsis episode (days) 5.5 ± 0.6
(1–24)
10.6 ± 1.8
(1–43)
0.005*
Antimicrobial therapy (days) 20.8 ± 2.4
(0–104)
18.5 ± 3.4
(0–64)
0.374
Number of surgical interventions 4.3 ± 0.3
(0–15)
2.5 ± 0.6
(0–12)
0.000*
Length of stay (days) 43.1 ± 3.2
(8–180)
29.9 ± 5.0
(3–113)
0.001*
Values are mean ± S.E. (min-max)
*Significant difference at p value < 0.05
ABSI Abbreviated Burn Severity Index, TBSA Total body surface area,
S.E. Standard error
Table 2 Analysis of individual procalcitonin (PCT) location
measures in survivor and non-survivor patients, showing
statistically significant differences for all parameters
Survivors Non-survivors p value
PCT
minimum
0.10 ± 0.01 (0.02–0.39) 2.84 ± 1.59 (0.06–48.39) 0.000*
PCT
median
0.57 ± 0.10 (0.05–4.31) 4.73 ± 1.93 (0.27–58.99) 0.000*
PCT
mean
2.04 ± 0.48 (0.05–26.28) 7.00 ± 1.98 (0.05–58.99) 0.000*
PCT
maximum
18.40 ± 4.38 (0.07–237.60) 28.07 ± 5.98 (0.87–145.40) 0.002*
Values are mean ± S.E. (min-max)
*Significant difference at p value < 0.05
PCT procalcitonin, S.E. Standard error
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December 2014 at Coimbra Burns Unit (CBU), a depart-
ment of Coimbra Hospital and University Center
(CHUC), in Portugal. Being a retrospective observational
study of patients from a suitably anonymized dataset, in-
volving only recording data from the medical record, the
Ethics Committee from CHUC, according to the Declar-
ation of Helsinki and Council for International Organi-
zations of Medical Sciences (CIOMS) International
Ethics Guidelines, waived the need of informed consent.
All the patients had a diagnosis of sepsis. This diagnosis
was done according to the American Burn Association
(ABA) criteria [23]: a clinical suspicion of infection
coupled with the presence of three or more of the follow-
ing parameters: temperature > 39 or < 36.5 °C; tachycardia
> 110 beats per minute; tachypnea > 25 breaths per mi-
nute or minute ventilation > 12 L/min; thrombocytopenia
< 100,000/μL; hyperglycemia (untreated plasma glucose >
200 mg/dL or intravenous glucose requirement > 7 U/h
over 24 h); and enteral feeding intolerance: abdominal dis-
tension or gastric residuals more than two times feeding
rate or diarrhea > 2500 mL/24 h.
PCT was measured with time-resolved amplified cryp-
tate emission (TRACE) technology (Kryptor PCT;
Brahms AG; Hennigsdorf, Germany). The sample was
factored by survival (68 survivors and 33 non-
survivors). The maximum value of PCT in each day of
the study was used for statistical analysis and when sam-
ples were not collected in some days (till a maximum of
5 days), the missing values of the interval were calcu-
lated as the median value between the PCT determina-
tions available.
Statistical analysis
Data were summarized by location measures (mean, me-
dian, minimum, maximum, quartiles) and dispersion
measures (standard error and range measures).
Fig. 1 Box plots of individual procalcitonin (PCT) median according to survivor and non-survivor groups. *p < 0.05 means significant differences
Table 3 Evolution of procalcitonin levels during the first
week of hospitalization for survivor and non-survivor groups
First week of hospitalization
Survivors Non-survivors
Day N Median Q1–Q3 N Median Q1–Q3
1 58 0.290 0.150–1.160 27 1.6600 0.405–7.995
2 65 0.345 0.170–1.650 28 2.0550 0.270–6.840
3 66 0.360 0.170–1.640 27 1.9800 0.565–3.220
4 67 0.420 0.175–1.155 26 2.0550 0.520–4.170
5 67 0.345 0.160–0.830 26 1.7900 0.700–4.370
6 68 0.330 0.155–0.785 25 1.3100 0.560–2.850
7 68 0.360 0.160–0.985 24 1.7000 0.730–5.555
Q1-Q3 1st Quartile- 3rd Quartile
Table 4 Evolution of procalcitonin levels in the last week of
hospitalization for survivor and non-survivor groups
Last week of hospitalization
Survivors Non-survivors
Day N Median Q1–Q3 N Median Q1–Q3
1 67 0.180 0.100–0.395 22 1.050 0.700–2.370
2 68 0.160 0.095–0.435 24 1.0150 0.435–2.830
3 68 0.150 0.080–0.400 26 1.1100 0.560–2.510
4 68 0.160 0.080–0.320 26 1.2000 0.460–2.825
5 68 0.150 0.070–0.355 27 1.4700 0.650–3.570
6 68 0.140 0.070–0.360 28 2.3650 0.710–5.820
7 68 0.125 0.070–0.365 31 3.8200 1.100–10.235
Q1-Q3 1st Quartile- 3rd Quartile
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The variables under study present a non-Gaussian distri-
bution. Under a nonparametric approach, the quantitative
variables were compared with the Mann-Whitney U tests
and qualitative variables were compared with the Pearson
chi-square test. Time variations of PCT levels were tested
using Friedman’s test and Kendall’s W ranges from 0 (no
agreement) to 1 (complete agreement).
To measure the difference effect size between the two
independent groups, the probability of superiority (PS)
was used. PS ranges from 0.0 to 1.0 and PS = 0.5 state
that there are no differences between the groups [A] and
PS = 0 or PS = 1 states the maximum effect.
Statistical analysis was performed with SPSS© 23.0
IBM© for Windows©, and in a statistical hypothesis
test, a p value ≤ 0.05 means the effect was consid-
ered significant.
Results
Sample description
Population characteristics are described in Table 1.
After factorization by survival, a significant hetero-
geneity was found between the two groups (68 survi-
vors and 33 non-survivors) for the age of the
patients, the Abbreviated Burn Severity Index (ABSI)
Fig. 2 Line plots of procalcitonin (PCT) levels evolution along the first week of hospitalization (a), last week of hospitalization (b), first week after suspicion
of sepsis (c), and first week of antimicrobial therapy (d), showing significant differences between survivor and non-survivor groups in a, b, c, d
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score (Additional file 1) [24], the TBSA burned, the
presence of inhalation injury, the need of mechanical
ventilation and its duration, the number of surgical
interventions, the duration of sepsis episode, and the
length of the stay at the burn unit. Heterogeneity
was not found for gender, burn degree, and duration
of antimicrobial therapy.
Table 2 shows the comparison of individual PCT loca-
tion measures, presenting significant differences between
survivors and non-survivors in all statistical parameters
(minimum, median, mean, maximum).
The box plots of individual median PCT levels for
each group are presented in Fig. 1, being significantly
lower for survivors.
PCT evolution along the first week of stay
Table 3 shows the evolution PCT levels in patients from
the survivor and non-survivor groups during the first
week of stay at CBU. The data presents missing values
of the PCT in some of the days of hospitalization and
this is the reason for this variation in the number of in-
dividuals by scenario. Differences between PCT levels of
patients from the survivor and non-survivor groups dur-
ing the first week of hospitalization are statistically sig-
nificant (Fig. 2a and Table 6).
PCT evolution along the last week of stay
The evolution of PCT levels for survivor and non-
survivor groups in their last week of stay at CBU is pre-
sented in Table 4. A statistically significant difference
was also demonstrated for this period of time (Fig. 2b
and Table 6).
PCT evolution in the first week after suspicion of sepsis
A statistical analysis of PCT evolution in the first week
after suspicion of sepsis, as defined by ABA criteria, was
also carried out. Data are presented in Table 5. A signifi-
cant difference between survivor and non-survivor
groups was detected (Fig. 2c and Table 6).
In order to compare the relative prognostic value of
PCT levels in each of the abovementioned periods (first
week of hospitalization, last week of hospitalization, and
first week after sepsis suspicion), statistical tests were
done, namely Friedman test p value and Mann-
Whitney U test p values with Sidak correction (Table 6).
Furthermore, the PS effect [25] was determined. The
results are transcribed in Table 7.
PCT evolution with antimicrobial therapy
No statistically significant difference was found between
the groups, but a within-group significant variation was
detected, with a progressive decline along the first 7 days,
supposedly due to antimicrobial action (Fig. 2d and
Table 8). When the analysis was extended to the 15th
day, it was found that PCT levels increased rapidly and
steadily until the day of death in non-survivors, what did
not happen in the survivor group, as seen in Fig. 3.
Discussion
Even acknowledging all advances in critical care, extensive
burns are still associated with high morbidity and mortality
mainly due to septic episodes [26, 27]. In the last years, di-
verse studies were published showing the utility of dosing
PCT levels as an aid to the diagnosis of systemic infection
in burn patients [28–34], particularly when a dynamic ap-
proach is used [35]. Notwithstanding the core decision
should rely on the clinical features and never on a bio-
marker alone [36], PCT dosing may support the suspect of
Table 5 Evolution of procalcitonin levels during the first week
after suspicion of sepsis for survivor and non-survivor groups
First week after suspicion of sepsis
Survivors Non-survivors
Day N Median Q1–Q3 N Median Q1–Q3
1 58 0.385 0.160–2.260 26 1.915 0.460–6.170
2 63 0.600 0.200–2.430 27 2.100 0.560–6.735
3 65 0.610 0.200–2.120 26 2.310 0.550–5.610
4 65 0.400 0.200–1.170 24 1.850 0.485–5.965
5 64 0.395 0.210–1.160 23 1.270 0.545–3.820
6 60 0.345 0.170–1.240 21 1.300 0.720–4.910
7 52 0.330 0.160–1.470 20 0.930 0.515–2.350
Q1-Q3 1st Quartile- 3rd Quartile
Table 6 Comparison between survivors and non-survivors during three periods of stay (first week of stay, last week of stay, and first
week after suspicion of sepsis)
Period Survivors Non-Survivors Global difference
p valuea Kendall’s W N p valuea Kendall’s W N p valueb
First week of stay 0.925 0.006 58 0.504 0.042 21 0.000*
Last week of stay 0.000* 0.162 67 0.050 0.095 22 0.000*
First week after suspicion of sepsis 0.000* 0.117 46 0.217 0.077 18 0.002*
Significant difference (*p value < 0.05)
aFriedman test p value
bThe minimum p value of all simultaneous Mann-Whitney U tests with Sidak correction
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ongoing and uncontrolled systemic infection when its
values keep rising, or at least does not subside in consecu-
tive analysis, indicating that something must be done to
control a probable septic process before it can lead to irre-
versible damage. Apart its potential to improve clinicians’
diagnostic capacity, PCT has been used with success at the
emergency departments [37, 38], to predict the prognosis
of suspected septic patients and to stratify them according
to the risk of death and the necessity of admission in inten-
sive care units (ICU) [39–41]. PCT levels at admission and,
much more reliable [42], its evolution on subsequent days
may give insights on the ultimate outcome, which is crucial
to clinical management and may be of great importance to
inform patient’s relatives and for judicial concerning [43–
47]. This valuable predictive power was not found for C-
reactive protein (CRP) or white blood cells counting,
another currently employed blood biomarkers [48–53]. The
prognostic power of PCT dosing has also been stated for
burned patients by Kim et al. [54] who, in a prospective ob-
servational study with a cohort of 175 patients, showed a
significant correlation between PCT levels and mortality
rate. In this context, it is worth to note, as referred by
Piroglu et al. [55], that clinical scoring systems used to pre-
dict mortality of intensive care patients, like Acute Physi-
ology and Chronic Health Evaluation Score II (APACHE
II), Simplified Acute Physiology Score (SAPS), Sequential
Organ Failure Assessment (SOFA), and Pediatric Risk of
Mortality (PRISM), do not include parameters specific for
burn patients, and these authors showed that combination
of the former score with PCT significantly increased its
accuracy. A prospectively study of Lavrentieva et al. [31],
including 145 patients, concluded that the maximum PCT
level has prognostic value in burn patients, and Mokline
et al. [32] found a close correlation of PCT levels with
sepsis severity, showing that increasing values were
linked with worse outcomes and vice versa.
Another important use of PCT dosing is guiding anti-
microbial therapy in septic ICU patients, which is becom-
ing generally accepted [56], supported by several trials
[57–62], systematic reviews, and meta-analysis [63–67];
however, some authors still consider that more studies on
its safety and efficacy are needed yet [68, 69]. Once a clin-
ical suspicion of sepsis is done, and in particular if corrob-
orated by abnormally elevated PCT levels, empirical
antimicrobial therapy, coupled with focus control when
feasible, must be immediately started because survival is
mostly depending on it and any delay, even hourly, is dir-
ectly related with an increase in mortality [13, 70, 71]. On
the other hand, there is an overwhelming acceptation that
a lengthening of antimicrobial therapy beyond that strictly
necessary to control the infectious process favors the de-
velopment of microbial resistance, contributing to the
soaring public health risk of having each time less sensi-
tive microorganisms and lack of antimicrobials to combat
them [72]. Many published works describe PCT kinetics
as a mirror of the evolution of the infectious episode [73–
75] as well as a trustable indicator of the antimicrobial
therapy efficacy, allowing an early de-escalation and/or
stopping of drug administration when its levels progress
and consistently subside [76, 77]. When PCT levels keep
elevated or even increasing, this is a sound indication that
therapy is not working and/or that there are still infectious
foci to clean, and if the situation is not rapidly controlled,
a bad outcome is foreseeable.
Several authors have discussed in recent works this
use of PCT, and a body of evidence is growing to sup-
port this approach. Jensen et al. in a trial (PASS Study)
[78] published in 2011 advised against PCT-guided anti-
microbial escalation, linking it to increased organ-related
harm and length of stay at the ICU, without improve-
ment in the outcomes. However, the sample analyzed
came from just one developed country with antimicro-
bial restriction and a traditionally low microbial resist-
ance. On the other hand, focus was not put on the
possibility of using PCT levels to help decision on anti-
biotherapy discontinuation neither a subgroup analysis
Table 7 Probability of superiority (PS) effect in procalcitonin levels due to mortality in different periods of stay (first week of stay, last
week of stay, and first week after suspicion of sepsis)
PS effect D1 D2 D3 D4 D5 D6 D7
First week of stay 0.29 0.26 0.25 0.25 0.21 0.24 0.25
Last week of stay 0.06 0.10 0.13 0.15 0.16 0.20 0.15
First weak after suspicion of sepsis 0.32 0.30 0.31 0.28 0.28 0.24 0.29
Table 8 Evolution of procalcitonin levels in the first week of
antimicrobial therapy for survivor and non-survivor groups
First week of antimicrobial therapy
Day Survivors Non-survivors
N Median Q1–Q3 N Median Q1–Q3
1 66 0.6300 0.240–3.020 24 2.080 0.945–2.810
2 68 0.5500 0.225–2.475 24 2.680 0.870–5.155
3 66 0.4950 0.220–1.300 24 1.945 0.750–7.205
4 66 0.4400 0.220–1.140 23 2.010 0.940–4.485
5 65 0.3500 0.170–1.140 22 1.065 0.550–4.490
6 61 0.3700 0.170–1.250 21 1.070 0.380–3.270
7 59 0.3700 0.175–0.920 21 0.960 0.660–2.420
Q1-Q3 1st Quartile- 3rd Quartile
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on burn patients was done. Nevertheless, and even if
antimicrobial escalation may be somewhat controversial,
PCT has proven to be very useful to monitor antimicro-
bials efficacy, with its levels paralleling clinical evolution,
and to indicate when it is safe to stop it without preju-
dice to the patients [79]. Indeed, this methodology has
proved to safely decrease antimicrobial consumption
[80] by reducing days of antimicrobial therapy with
strong potential to lower resistance development. This
approach has already been validated for use in ICUs,
with proven reduction of antimicrobial consumption
without increase in morbidity or mortality [81]. Indeed,
de Jong et al., in the largest prospective study in ICU pa-
tients published to date (SAPS Study) [61], were even
able to show a significant reduction of mortality rate.
The ever wider diffusion of PCT test, reducing its costs,
and its efficacy in this setting, made also possible for
some authors to consider it as probably cost-effective
[82–86]. In a recent paper, Lavrentieva et al. [87] re-
ported significantly shorter durations of antibiotic treat-
ment in a PCT-guided group of burns patients
compared to controls without differences in main out-
come characteristics, including mortality rate, length of
mechanical ventilation, and length of stay.
Among the limitations of this study are naturally its
single-center, retrospective observational character as
well as lacking of subgroup analysis according to con-
comitant pathologies. The definition of a precise cut-
off of PCT levels for predicting outcomes or stopping
antimicrobial therapy was also beyond the scope of
this analysis and, as recognized in the literature, it
will always be dependent on patient characteristics
and facility features, and it is PCT kinetics that de-
served authors attention, in spite of 100 ng/mL was
often taken as an alert signal. On the positive aspects
are the sample size and the strict use of ABA burn
sepsis definitions for inclusion criteria. The strength
of results from the present study would be largely en-
hanced by a desirable prospective multicentric trial.
The use of prognostic biomarkers in order to pre-
dict outcomes as well for guiding antimicrobial ther-
apy in sepsis patients is nowadays a common
practice in intensive care wards. As anytime more
acknowledged in the literature, antimicrobial stew-
ardship programs employing current available bio-
markers or preferably, a panel of diverse ones,
always associated with repeated clinical evaluation,
may decisively improve patients’ stratification and
antimicrobial use, optimizing patients outcome, re-
ducing the spread of microbial resistance, and cut-
ting financial burden [88–93]. Meanwhile more
sophisticated and individualized system-based (inte-
grating genomics, metabolomics, and proteomics)
[94–96] data are not available to more accurately
predict outcomes and tailor treatment options for
burn victims, as well as other intensive care patients,
PCT dosing will remain one of the more useful tools
to help clinicians decisions.
Fig. 3 Line plots of procalcitonin (PCT) evolution in the first 15 days of antimicrobial therapy
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Conclusion
In spite of its limitations, the close correlation be-
tween PCT levels and patients’ outcomes statistically
demonstrated in the present work backs its use for
prognosis determination in severe burn patients.
Additionally, this study showed that the persistency
of abnormally elevated PCT along the days of anti-
microbial therapy was linked with poor outcomes in
this set of patients, opposed to what happens when
their levels fall in a consistent way, reflecting its
efficacy.
Prospective multicentric studies would surely give
more strength to the generalization of PCT use for prog-
nosis and antimicrobial stewardship in burn patients and
are much needed.
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Abstract
Background: Early sepsis diagnosis is crucial for the correct management of burn patients, and it clearly influences
outcomes. The systemic inflammatory response triggered by burns mimics sepsis presentation and complicates early
sepsis diagnosis. Biomarkers were advocated to aid the diagnosis of early sepsis. Serum procalcitonin (PCT) exhibits fair
accuracy and good correlation with sepsis severity, being used in diverse clinical settings. However, few studies have
evaluated perioperative changes in PCT levels in burn patients. The present study evaluated PCT kinetics during the
first days after burn injury and subsequent surgical interventions to assess PCT utility in distinguishing septic from non-
septic inflammatory responses.
Methods: This study was a retrospective observational study of all burn patients admitted to the Coimbra Burns Unit
(Portugal) between January 2011 and December 2014 who presented with a total burn surface area ≥ 15% and who
underwent subsequent surgery. PCT kinetics were investigated a) during the first five days after burn injury and b)
preoperatively during the five days after surgery in three subsets of patients, including those with no preoperative and
no postoperative sepsis (NN), no preoperative but postoperative sepsis (NS), and preoperative and postoperative sepsis
(SS). A total of 145 patients met the selection criteria and were included in the analysis.
Results: PCT levels in the first five days after burn injury were significantly higher in patients who developed at least
one sepsis episode (n = 85) compared with patients who did not develop sepsis (n = 60). PCT values > 1.00 ng/mL
were clearly associated with sepsis. Study participants (n = 145) underwent a total of 283 surgical interventions. Their
distribution by preoperative/postoperative sepsis status was 142 (50.2%) in NN; 62 (21.9%) in NS; and 79 (27.9%) in SS.
PCT values exhibited a parallel course in the three groups that peaked on the second postoperative day and returned
to preoperative levels on the third day or later. The lowest PCT values were found in NN, and the highest values were
observed in SS; the NS values were intermediate.
Conclusions: PCT kinetics coupled with a clinical examination may be helpful for sepsis diagnosis during the first days
after burn injury and burn surgery.
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Background
An early diagnosis of sepsis is of the utmost importance
for the correct management of burn patients because it
has a marked impact on treatment outcomes and survival
[1]. Sepsis can lead to multiple organ dysfunction syn-
drome (MODS), which is the cause of most deaths in burn
units [2]. Therefore, a prompt sepsis diagnosis and the
immediate initiation of antimicrobial therapy are needed
to reduce morbidity and mortality. However, the unneces-
sary administration of antimicrobials is often associated
with adverse effects, increased costs and the emergence
and spread of antimicrobial resistance.
It is clinically difficult to identify patients who are
developing sepsis because the overwhelming systemic
inflammatory response triggered by burn trauma mimics
the signs and symptoms of sepsis [3]. A definitive diagno-
sis of sepsis requires microbiological cultures, but the re-
sults are not available for 24 to 48 h, and false negative
results are found in 20–30% of cases. Therefore, the devel-
opment of complementary tools for sepsis diagnosis, such
as the use of biomarkers, is necessary [4].
Biomarkers and their kinetics may aid the clinical
examination in the differentiation of infectious from
non-infectious inflammatory responses [5, 6]. Numerous
sepsis biomarkers are described in the literature [7], and
procalcitonin (PCT) is one of the most studied biomarkers.
PCT exhibits the best discriminative power of all of the bio-
markers that are available at most hospital facilities [8, 9].
Thyroid C cells primarily secrete PCT in healthy subjects,
and it is barely detected in blood (< 0.01 ng/mL). Many
other cell types (liver, kidney, adipocytes, etc.) secrete PCT
in response to direct or indirect infectious stimuli during
septic episodes, and it is massively released into the blood-
stream at concentrations that reach 1000 times its normal
values [10]. Increased PCT is noticeable 2–4 h after sepsis
onset and peaks at 24–48 h. PCT levels decrease by 50%
every 1–1.5 days (half-life) when the infectious process
is controlled [11]. PCT levels are highly correlated with
bloodstream infections [12], and a recent meta-analysis
demonstrated that elevated PCT levels and PCT non-
clearance were related with an increased risk of sepsis
and a higher mortality rate [13]. PCT is accurate for
sepsis diagnosis, and its kinetics exhibit good correlation
with sepsis severity [14]. Therefore, PCT is recommended
in diverse clinical settings, including the exclusion of a
bacterial cause in lower respiratory infections [15] as
well as the diagnosis, stratification, prognosis [16, 17]
and antimicrobial administration guidance in septic
patients [18] and the diagnosis of postoperative infections
[19, 20]. However, the utility of PCT in burn patients
was questioned because of the high rate of false-positive
results from the systemic inflammatory response in-
duced by burn injury and subsequent surgical interven-
tions [21, 22].
The present study evaluated PCT kinetics after a burn
episode and the surgical intervention(s) needed for its
treatment to assess its utility in the differential diagnosis
between septic and non-septic inflammatory responses.
Methods
Study plan
This retrospective observational study used clinical and
laboratory data collected from the health records of all
burn patients admitted to Coimbra Burns Unit (CBU), a
department of Coimbra Hospital and University Centre
(CHUC), a tertiary referral hospital in Portugal, between
January 2011 and December 2014, who presented with a
15% or more total burn surface area (TBSA) and who
underwent subsequent surgery during their hospitalization.
A total of 145 patients met the selection criteria, and their
data were available for analysis.
Sepsis was diagnosed according to the American Burn
Association (ABA) criteria [23]: presence, in at least one
of the initial five days, of a clinical suspicion of infection
coupled with at least three of the following findings:
temperature > 39 °C or < 36.5 °C, tachycardia > 110 beats/
min, tachypnea > 25 breaths/min or minute ventilation >
12 L/min, thrombocytopenia < 100,000/mL, hyperglycaemia
(untreated plasma glucose > 200 mg/dL or intravenous glu-
cose requirement > 7 U/h over 24 h), and enteral feeding
intolerance (abdominal distension or gastric residuals more
than two times feeding rate or diarrhoea > 2500 mL).
Serum PCTconcentrations were measured using TRACE©
(time-resolved amplified cryptate emission) technology
(Kryptor© PCT; Brahms© AG; Hennigsdorf, Germany).
PCT kinetics were evaluated in the first five days after
burn injury in the entire study population, preoperatively
and during the five days after surgery in three subsets of
patients: no preoperative and no postoperative sepsis
(NN), no preoperative but postoperative sepsis (NS), and
preoperative and postoperative sepsis (SS).
Statistical analysis
The maximum value of PCT on each day of the study
was used for statistical analyses.
Qualitative variables (e.g., gender and mortality) are de-
scribed as counts, and quantitative variables (e.g., TBSA
and ABSI - Abbreviated Burn Severity Index: see Additional
file 1) are described as the means and corresponding stand-
ard deviations. The number of surgical interventions
and PCT values by subgroup are described as medians
and interquartile ranges (IQR). Comparisons between
sepsis and no sepsis groups were performed using the
Mann-Whitney test for quantitative variables and the
Fisher’s exact test for qualitative variables. Time compari-
sons of PCT levels were performed using Friedman’s test.
Receiver operating characteristic (ROC) curves and
comparative analysis of the area under the curve (AUC)
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were performed to evaluate the discriminatory power of
PCT levels on consecutive days.
Statistical analysis was performed using SPSS© 23.0
IBM© for Windows©, and a p-value ≤0.05 was consid-
ered significant.
Results
Table 1 presents the primary demographic and baseline
characteristics of the study population, which consisted
of 84 males and 61 females. The sepsis (n = 85) and
non-sepsis (n = 60) groups showed no significant differ-
ences in terms of gender or age, but they were significantly
different in terms of ABSI score, TBSA and mortality.
The analysis of PCT levels during the first five days
after the burn episode showed a statistically significant
difference between the group of patients who developed
at least one sepsis episode during that time and the
group of patients who did not develop sepsis (Fig. 1).
PCT values over 1.00 ng/mL were clearly associated with
septic processes (p < 0.001, Mann-Whiney U test, Table 2).
ROC curves and the AUC were performed to evaluate the
discriminatory power of PCT over consecutive days. These
results demonstrated that the discriminatory power of PCT
levels increased over time (Table 3 and Fig. 2).
All patients (n = 145) underwent at least one surgical
intervention, with a cumulative 283 surgical interven-
tions. Each patient was subjected to a median of three
interventions, with an IQR of [2.00–5.25]. All interven-
tions were performed under general anaesthesia and
were classified as clean-contaminated. The interventions
consisted primarily of escharectomies, skin autografts
and flaps, and digits/limb amputations to a lesser extent.
To assess the influence of surgical trauma on PCT
concentrations, PCT evolution from the day before the
operation (D0) until the fifth postoperative day (D5) was
analysed. Differences in the time evolution of PCT between
the sepsis and non-sepsis groups were statistically sig-
nificant (Table 4), and the discriminatory power in-
creased over time as shown by the ROC curve analysis
(Table 5 and Fig. 3).
Table 1 Study population
Characteristics No Sepsis Sepsis# p-value
Number of patients 85 60
Gender (male/female) 45/40 39/21 0.115
Age (years)$ 56.49 (±18.15) 58.43(±21.89) 0.517
ABSI scorea 7.69 (±2.82) 9.17 (±2.20) 0.000*
TBSA (%)$ 29.97 (±19.94) 34.6 (±17.26) 0.000*
Mortality (No/Yes) 84/1 24/36 0.004*
*p-values < 0.05
$Values are Median (Q1-Q3)
#At least one day with sepsis in the first five days after burn episode
aDescription in Annex I
Fig. 1 Median PCT levels observed in in the first five days after burn injury in septic (Yes) and non-septic (No) patients
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Regarding the preoperative/postoperative sepsis status,
median values had a parallel course in the three groups
(Fig. 4). Values peaked in the second postoperative day
and returned to preoperative levels on the third day or
later. The lowest values were found in the NN group,
which included 142 surgical interventions in patients
without preoperative sepsis and who did not develop
postoperative sepsis through D5 (50.2%). The highest
values were observed in the SS group, which included 62
surgical interventions in patients with pre- and postop-
erative sepsis (21.9%). Group NS exhibited PCT values
roughly in the middle range between the other two
groups and included 79 surgical interventions in patients
who did not exhibit septic processes preoperatively but
developed sepsis on at least one of the five days after
surgery (27.9%). The kinetics of the PCT levels within
each group (Table 3) were significantly different between
days after surgery in the absence (NN) or presence of
sepsis (NS and SS).
Discussion
The present study included a sample of 145 burn patients
from the CBU, and PCT levels were significantly different
between septic and non-septic patients during the first five
days after burn injury. The results indicate that PCT
values evolved in parallel with sepsis development and the
antimicrobial therapy effect. In this important population,
PCT consistently showed good potential to discriminate
between septic and non-septic patients, particularly when
frequent PCT assays were performed and when its kinetics
were dynamically assessed.
To evaluate PCT performance after surgical interventions
and to investigate whether surgical trauma alone could re-
duce the accuracy of the diagnosis of postoperative sepsis,
this study included a substantial and diversified number of
interventions performed in the three subsets of patients
who were organized according to the existence or absence
of preoperative sepsis and the development or worsening of
sepsis after surgery. PCT levels increased modestly and rap-
idly returned to basal levels after the second postoperative
day in patients with no preoperative or postoperative sepsis
episodes. Patients with increased preoperative PCT values
that corresponded to preoperative sepsis exhibited PCT
kinetics with a higher peak on the second postoperative
day, which was presumably related to the additive incre-
ment of PCT of surgical trauma. PCT values returned to
the initial values when antimicrobial therapy was adminis-
tered. PCT levels in patients who only developed sepsis
after surgery exhibited a parallel evolution to the already
septic patients but generally with lower absolute values.
Therefore, PCT is useful for sepsis diagnosis in cases of sur-
gical intervention when preoperative PCT values are known
because PCT kinetics follow the same pattern of evolution
in cases of sepsis as in other critical patients.
The search for sepsis biomarkers is an exciting and
never-ending story [24, 25]. Diverse approaches were used
to identify more precise, practical, quicker, safer and
cheaper chemicals or physical changes that may indicate
the urgent need and adequacy of antimicrobial therapy or
its redundancy to reduce adverse events, microbial resist-
ance and financial costs. Current research is more focused
on molecular (PCR, MALDI-TOF) and/or system-based
(genomics, transcriptomics, proteonomics, metabolomics)
methods for sepsis diagnosis [26–29], but these techniques
are not fully developed, practical or widely available.
An ideal biomarker is not developed, and the use of
PCT as an early distinction between actual septic patients
and patients with merely systemic inflammatory signals
and symptoms during the first days after hospital admis-
sion has been largely discussed in the medical literature in
the last two decades [30–35]. PCT is a useful but not ideal
Table 2 Statistical analysis of PCT kinetics in the first five days after burn injury in septic and non-septic patients
Sepsis Statistic D1 D2 D3 D4 D5 p-value*
No n 64 70 72 69 62
Median [IQR] 0.215 [0.090–0.578] 0.205 [0.09–0.723] 0.210 [0.08–0.668] 0.215 [0.102–0.695] 0.213 [0.118–0.618] 0.557
n 50 53 52 53 52
Yes Median [IQR] 1.085 [0.188–5.440] 1.650 [0.235–4.010] 1.130 [0.335–2.920] 1.060 [0.355–2.927] 0.725 [0.340–2.105] 0.288
p-value** 0.001 0.000 0.000 0.000 0.000
*Friedman test
**Mann-Whiney U test
Table 3 ROC curves for the discriminatory power of PCT levels
between septic and non-septic patients in the first five days
after burn injury
Area Under the Curve (AUROC)
Day Area Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
D1 0.646 0.532 0.759
D2 0.704 0.598 0.810
D3 0.746 0.647 0.845
D4 0.752 0.654 0.850
D5 0.741 0.641 0.841
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biomarker, particularly due to its negative predictive
power [36], which led to its inclusion in algorithms for
sepsis management [37, 38]. The use of serial measure-
ments instead of a single observation reinforces the pre-
dictive power of PCT and reduces the risks of false
negatives and false positives [39–43]. The same consider-
ations are valid for the use of PCT in the investigation of
suspected postoperative sepsis [44], which is currently per-
formed after many types of surgical procedures [45–49].
PCT accuracy in burn patients is controversial [21,
22, 50, 51]. Burn patients are generally excluded from
sepsis studies and clinical trials based on the simplistic
assumption that PCT levels are always elevated in burn
patients as a result of the non-septic inflammatory systemic
response related to burn trauma. However, several studies
consistently demonstrated different PCT kinetics in burn
patients based on the presence or absence of systemic
infection [52–55]. Three recent meta-analysis also vali-
dated the use of PCT for sepsis diagnosis in these patients
[56–58]. PCT evolution is predictable in both cases, and it
provides a reliable means to identify septic processes,
which was first referred to by von Heimburg et al. in 1998
Fig. 2 ROC Curves for the discriminatory power of PCT levels between septic and non-septic patients in the first five days after burn injury
Table 4 Statistical analysis of PCT kinetics from preoperative day (D0) till the fifth postoperative day (D5) for NN, NS and SS groups
Sepsis Statistic D0 D1 D2 D3 D4 D5 p-value*
NN n 212 208 198 186 163 149
Median [IQR] 0.190
[0.110–0.560]
0.200
[0.101–0.615]
0.280
[0.120–0.758]
0.223
[0.118–0.553]
0.195
[0.110–0.430]
0.180
[0.100–0.360]
0.000
NS n 104 103 102 100 87 80
Median [IQR] 0.405
[0.219–0.935]
0.510
[0.240–1.360]
0.640
[0.313–1.590]
0.625
[0.283–1.438]
0.540
[0.260–1.970]
0.515
[0.273–2.045]
0.000
SS n 74 74 74 69 65 62
Median [IQR] 0.653
[0.233–2.193]
0.790
[0.288–2.518]
1.115
[0.413–2.990]
0.880
[0.380–3.115]
0.710
[0.300–1.950]
0.580
[0.248–1.520]
0.000
p-value** 0.000 0.000 0.000 0.000 0.000 0.000
Multiple comparison (p-value***)
(NN,NS) 0.000 0.000 0.000 0.000 0.000 0.000
(NN,SS) 0.000 0.000 0.000 0.000 0.000 0.000
(NS,SS) 0.339 0.225 0.135 0.294 1 1
*Friedman test
**Kruskal Wallis test
***Mann-Whiney U test with Bonferroni correction
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[59]. The immediate inflammatory burst elevates PCT
levels after burn injury, independent of infection, and
grossly correlates with TBSA, but it rarely surpasses
2.0 ng/mL [60, 61]. The maximum PCT value is reached
within 24–48 h in the absence of sepsis and returns to nor-
mal values (1.0–1.5 ng/mL or less) by the end of the third
day. PCT levels continue increasing in the presence of sep-
sis and rapidly reach values greater than 5–100 ng/mL.
PCT levels only diminish with antimicrobial therapy or
terminal immunosuppression, as observed in other forms
of severe trauma [62]. Lavrentieva et al. analysed a sample
of 145 burn patients and found increased PCT levels during
the first 24 h after a burn episode, which subsided in
non-septic patients and continued increasing in septic
patients. These authors demonstrated an inverse
relationship of PCT level tendency with antimicrobial
therapy efficacy. They proposed a cut-off of 1.5 ng/mL
to distinguish between septic and non-septic patients
[63]. Egea-Guerrero et al. [64] and Kim et al. [65] found
the same PCT kinetics and approximate cutoffs.
PCT exhibited a similar kinetics pattern after surgical
intervention [66], but preoperative PCT levels must be
known to use these levels to discriminate between the
postoperative physiological inflammatory response and
postoperative sepsis. Preoperative PCT levels are related
to the presence or absence of an ongoing sepsis process
and possible ongoing antimicrobial therapy, which naturally
influence baseline values [67]. To the best of our know-
ledge, the present study is the first study to specifically
address PCT kinetics after surgical procedures in burn pa-
tients and demonstrate that this biomarker maintains its
performance in this particular set of patients, even in the
presence of preoperative sepsis.
PCT levels coupled with rigorous clinical monitoring
and blood cultures as the diagnostic cornerstone [68] may
help confirm or exclude sepsis in patients during the acute
phase after burn trauma and ascertain the presence of
postoperative sepsis in burn patients. Neither immunode-
pression [69] nor corticotherapy [70] affected the diagnos-
tic performance of PCT, as opposed to other biomarkers,
and PCT also distinguishes contamination from actual
bloodstream infection [71]. The use of PCT dosing may
inclusively reduce healthcare costs and avoid the superflu-
ous use of antimicrobials and consequent increments on
microbial resistance [72, 73].
Table 5 ROC curves for the discriminatory power of PCT levels
between septic and non-septic patients preoperatively and in
the first five days after burn surgery
Area Under the Curve (AUROC)
Day Area Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
D0 0.662 0.591 0.733
D1 0.701 0.633 0.770
D2 0.717 0.649 0.784
D3 0.752 0.686 0.815
D4 0.760 0.696 0.824
D5 0.771 0.708 0.834
Fig. 3 ROC Curves for the discriminatory power of PCT levels between septic and non-septic patients preoperatively and in the first five days
after burn surgery
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The present study also presents some limitations. First,
it was a single-centre, retrospective observational study,
and the results require confirmation using prospective
multicentre trials. Second, the precise influence of anti-
microbial therapy in septic patients could not be evaluated
because of ethical considerations that naturally prevent
antimicrobial denial in face of septic episodes. Third, sub-
group analyses according to the total burned surface area
(TBSA) and the severity of patients’ attainment, for in-
stance, using the Abbreviated Burn Severity Index (ABSI),
was not performed. However, the use of defined and inter-
nationally accepted criteria for the clinical suspicion of
burn sepsis, the homogeneity of therapeutic procedures,
and the use of a standard methodology for the collection,
recording and statistical analysis of the data are clearly
strengths of the present study.
Conclusion
The present study was performed in 145 burn patients
who underwent a high and diversified number of surgi-
cal interventions. The results allow us to conclude that
1) PCT kinetics may aid in the differential diagnosis be-
tween true sepsis and the normal inflammatory response
to burn trauma in the first days after burn injury; and 2)
PCT kinetics may be used to identify postoperative sep-
sis in burn patients who undergo surgical interventions
during their stay in burn units.
Prospective multicentre studies in adult and paediatric
burn patients are needed to confirm these findings and
compare PCT and other biomarkers in these contexts.
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Evaluation of Procalcitonin Accuracy for the Distinction 
Between Gram-Negative and Gram-Positive Bacterial Sepsis 
in Burn Patients
Luís Cabral, MD,*,†,  Vera Afreixo, PhD,‡ Rita Meireles, MD,* Miguel Vaz, MD,* João-Gonçalo Frade, PhD,||,$ 
Catarina Chaves, MD,|| Marisa Caetano, PharmD,¶ Luís Almeida, PhD,** and José-Artur Paiva, PhD,††,‡‡
Sepsis is the main cause of death in burns. Early institution of antimicrobial therapy is crucial to optimize outcomes 
but superfluous therapy increases adverse events, microbial resistance, and costs. Blood cultures are the gold standard 
for diagnosis but can take 48 to 72 hours. Biomarkers are used to help sepsis diagnosis and distinction between 
Gram-negative and Gram-positive bacterial cause. The aim of this work is to evaluate procalcitonin (PCT) accuracy 
for this distinction in burn patients. Retrospective observational study of adult septic burn patients with ≥15% 
total burn surface area admitted from January 2011 to December 2014 at a Burn Unit in Portugal. A statistical 
analysis was done, evaluating the correlation between PCT levels on the day of the first positive blood culture and 
microbiological data for Gram-negative and Grand-positive bacteria. Patients with mixed bacterial and/or fungal 
blood cultures were excluded. Data were summarized by quartiles statistics. Blood cultures were positive in 189 
patients: 75 (39.7%) showed growth for Gram-negative and 114 (60.3%) for Gram-positive bacteria. Patients with 
Gram-negative bacteria have significantly higher PCT levels. Receiver operating characteristic curve analysis showed 
accuracy for Gram-negative discrimination with area under the curve = 0.687. Most elevated levels were related to 
nonfermentative Gram-negative bacteria and by Klebsiella pneumoniae and other Enterobacteriaceae. PCT levels 
were significantly higher in burn patients with Gram-negative sepsis comparing to patients with Gram-positive 
sepsis and controls. The determination of PCT levels may help the choice of empirical antimicrobial therapy while 
microbiological culture results are not available, despite not fully ensuring the desirable degree of precision.
An early and adequate antimicrobial therapy is the main step 
for the management of septic patients.1 Unfortunately, dif-
ferential diagnosis between sepsis and the systemic inflam-
matory response triggered by trauma is difficult, particularly 
in burn patients where the usual clinical signs of sepsis are 
frequently present even in the absence of microbial infec-
tion.2 For instance, burn injuries leading to upregulation 
of the hypothalamic thermal center, physiologic release of 
catecholamines and cytokines, shift of fluids and the con-
sequent cardiovascular changes, can produce hyperthermia, 
tachycardia, hypotension, etc., that are transitory and do not 
reflect any microbial invasion but just a tentative of adjust-
ment of human body systems to the changes in the homeo-
static equilibrium.
*Department of Plastic Surgery and Burns Unit, Coimbra University Hospital 
Centre (CHUC), Portugal; 
†Autonomous Section of Health Sciences (SACS), University of Aveiro, Portugal; 
‡CIDMA—Center for Research and Development in Mathematics and 
Applications, iBiMED—Institute for Biomedicine, Department of 
Mathematics, University of Aveiro, Portugal; 
||Clinical Pathology Department, Coimbra University Hospital Centre (CHUC), 
Portugal; 
$Escola Superior de Saúde, Instituto Politécnico de Leiria, Portugal; 
¶Pharmacy Department, Coimbra University Hospital Centre (CHUC), 
Portugal; 
**MedinUP, Department of Pharmacology and Therapeutics, Faculty of 
Medicine, University of Porto, Portugal; 
††Department of Emergency and Intensive Care Medicine, Centro Hospitalar 
São João, Porto, Portugal; 
‡‡Grupo de Infecção e Sépsis, Faculty of Medicine, University of Porto, Portugal 
© American Burn Association 2018. All rights reserved. For permissions, please 
e-mail: journals.permissions@oup.com.
Funding. V.A. work was supported by Portuguese funds through the CIDMA—
Center for Research and Development in Mathematics and Applications by 
the Portuguese Foundation for Science and Technology (FCT—Fundação para 
a Ciência e a Tecnologia), within project ID/MAT/04106/2013. On behalf 
of all the other authors, the corresponding author states that none of them has 
received any funding for this work.
Conflict of interest statement. All authors state that there are no conflicts of 
interest.
ORIGINAL ARTICLE
doi:10.1093/jbcr/iry058
Authors’ Contributions. All authors have read the manuscript and agreed 
to its content, are accountable for all aspects of the accuracy and integrity 
of the manuscript in accordance with ICMJE criteria and gave their 
consent for publication. L.C., V.A., C.C., and M.C. designed the study, 
interpreted data, and draft the manuscript. V.A. was responsible for most 
of statistical analysis. R.M., M.V., and J.G.F. were responsible for data 
acquisition, search of literature, and made suggestions for its integration 
along the manuscript. C.C. made also substantial intellectual contributions 
for the Introduction and Discussion sections of the manuscript. L.A. and 
J.A.P. review the manuscript, and made useful suggestions for Discussion 
and Conclusions sections.
Ethics Approval and Consent to Participate. Being a retrospective observational 
study of patients from an anonymized dataset, involving only recording data 
from the medical record, the Ethics Committee from Coimbra University 
Hospital Centre (CHUC), waived the need of informed consent according to 
Declaration of Helsinki and CIOMS International Ethics Guidelines.
Consent for Publication. As all data was anonymized, this study does not contain 
any individual person’s data in any form (including individual details, 
images, or videos) and accordingly consent for publication was waived.
Availability of Data and Material. The data that support the findings of this 
study are available from the datasets of the Informatics Department of 
Coimbra University Hospital Centre but restrictions apply to the availability 
of these data, which were used under license for the current study, and so are 
not publicly available. Data are, however, available from the authors, upon 
reasonable request and after permission of the Ethics Committee from Coimbra 
University Hospital Centre.
Address correspondence to Luis Cabral, MD, Unidade de Queimados—CHUC, 
Av. Bissaya Barreto s/n, 3000–075 Coimbra Portugal. Email: jlacabral@
gmail.com
D
ow
nloaded from
 https://academ
ic.oup.com
/jbcr/article-abstract/40/1/112/5183274 by guest on 27 D
ecem
ber 2018
73
Journal of Burn Care & Research 
Volume 40, Number 1 Cabral et al  113
The gold standard for sepsis diagnosis still relies on the 
microbiological growth in blood cultures,3 which can take 
as long as 48 to 72 hours, according to different facilities,4 
and the antimicrobial sensibility tests may be available even 
later. On the other hand, the adequacy of antimicrobial 
therapy is obviously related with the appropriateness of the 
chosen drugs, that is, the selection of the most efficacious 
drug against the causative microorganism. In practical terms, 
physicians have to assess the presence of sepsis in a complex 
clinical setting, with great chance of misdiagnosis (false pos-
itive or false negative), and in most cases to wait 2 days to 
confirm their suspicion, having (or not) prescribed an antimi-
crobial therapy that may be inefficacious against the causative 
bug, allowing the septic process to progress and increasing 
the likelihood of a fatal outcome. Moreover, a superfluous 
or an inappropriate antimicrobial therapy presents risks of 
adverse events for the patient and stimulates the development 
of microbial resistance, besides increasing costs.5 In conclu-
sion as described in a seminal work by Kumar et al,6 it is of 
outstanding importance the prompt institution of an effective 
antimicrobial therapy, avoiding the serious risks present when 
this is not timely done.
In the last decade, biomarkers have been employed to help 
sepsis diagnosis and antimicrobial prescription and stopping. 
Together with infection control measures and antimicrobial 
therapy protocols, the use of biomarkers constitutes the back-
bone of most antimicrobial stewardship programs.7 From a 
multitude of clinical and biochemical biomarkers described 
in literature, procalcitonin (PCT) became one of the most 
employed due to 1) its relatively good accuracy for the diag-
nosis of septic and nonseptic patients since the first hours 
of microbial invasion, helping the decision to start or post-
pone antimicrobial therapy, particularly if used in a dynamic 
approach; 2)  correlation between PCT levels and sepsis 
severity, and 3)  its rapid fall when infection is controlled.8 
Furthermore, significant differences in PCT levels have been 
found according to the causative pathogens, namely between 
Gram-negative and Gram-positive bacteria, which facilitates 
the choice of the drugs to be empirically used meanwhile 
blood culture results and sensibility tests are not available.
Even being controversial for some authors, determina-
tion of PCT serum levels has been consistently advocated for 
the diagnosis, prognosis, and antimicrobial stewardship in 
burn patients. Taking into account the different therapeutic 
approach to different pathogens, it is worthwhile to evaluate 
the discriminative potential of PCT to set the more appropri-
ate empirical therapy. The aim of this work is to size up PCT 
performance for the differential diagnosis between sepsis by 
Gram-negative and Gram-positive bacteria in a large sample 
of burn patients.
MATERIALS AND METHODS
Patient Informed Consent
Considering that this was an observational study using anony-
mized retrospective data, the Independent Ethics Committee 
(Comissão de Ética para a Saúde, Coimbra Hospital University 
Center—CHUC, Coimbra, Portugal) waived the need of 
informed consent.
Study Plan
Data for this retrospective observational study was collected 
from the clinical files and laboratory electronic records of con-
secutive burn patients with 15% or more of total burn sur-
face area, admitted from January 2011 to December 2014 at 
Coimbra Burn Unit (CBU), a department of CHUC. All the 
patients had positive blood cultures and clinical diagnosis of 
sepsis, following the American Burn Association criteria9: sus-
picion of infection coupled with the presence of three or more 
of the following parameters: temperature >39°C or <36.5°C; 
tachycardia >110 beats/min; tachypnea >25 breaths/ min 
or ventilation >12 l/min; thrombocytopenia <100,000/
ml; hyperglycemia (untreated plasma glucose > 200 mg/dl 
or intravenous glucose requirement > 7 U/h over 24 hours; 
enteral feeding intolerance: abdominal distension or gas-
tric residuals more than two times feeding rate or diarrhea 
>2500 ml.
Blood cultures were obtained in a standardized way. Three
samples were collected by sterile venepuncture in septic 
patients. Except when immediate antimicrobial therapy has to 
be initiated due to sound clinical or laboratorial sepsis suspi-
cion, the collects were done in the morning (7–8 am). This 
collect was repeated every 2 days until clinical resolution and 
PCT normalization.
Using sample patients who never developed sepsis during 
its stay at CBU as controls, a statistical analysis was done to 
evaluate possible correlation of PCT levels on the day of the 
collection of the first positive blood culture with microbiolog-
ical data, according to two groups of microorganisms: Gram-
negative and Grand-positive bacteria. To avoid potential bias 
and simplify the analysis, patients with positive mixed bacterial 
and/or fungal blood cultures were excluded from the study. 
When a patient had more different microorganisms present in 
the blood cultures at different timepoints, only PCT levels of 
the first identification were subjected to analysis. If a patient 
had more than a PCT measurement on the day of collection, 
the highest value was used for the analysis. PCT was measured 
with TRACE© (time-resolved amplified cryptate emission) 
technology (Kryptor© PCT; Brahms© AG; Hennigsdorf, 
Germany).
Statistical Analysis
Data were summarized by quartiles statistics. The quantita-
tive variables under study showed a non-Gaussian distribu-
tion and thus a nonparametric approach (Kruskall–Wallis and 
Mann–Whitney tests) was used to compare quantitative vari-
ables. Qualitative variables were compared with the Pearson 
chi-square test. For pairwise comparisons, the Bonferroni-
correction was applied.
Receiver operating characteristic (ROC) curves, in par-
ticular the area under the curve (AUC), were performed to 
evaluate PCT ability in Gram-negative and Gram-positive dis-
crimination. Sensitivity, specificity, positive and negative pre-
dictive values were calculated for some cutoff values including 
the best cutoff defined by the maximum value of Youden 
index (J = sensitivity + specificity − 1).
Statistical analysis was performed with SPSS© 25.0 IBM© 
for Windows©. A p value of less than .05 was set as the level 
of significance and the confidence intervals are reported with 
95% confidence level.
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RESULTS
The sample under analysis was composed 438 burn patients. 
Among these patients, 249 (56.8%) did not fulfill American 
Burn Association sepsis criteria neither had any growth in their 
blood cultures during their stay at CBU, being deemed to 
serve as controls. Blood cultures were positive in 189 (43.2%) 
patients; among from these, 75 patients (39.7%) showed 
growth for Gram-negative bacteria and 114 (60.3%) showed 
growth for Gram-positive bacteria (Table 1). The median age 
was 62 years for controls, 66 years for patients with sepsis by 
Gram-negative bacteria and 69 years for patients with sepsis 
by Gram-positive bacteria; the difference among groups did 
not reach statistical significance. The same was true for gender 
distribution, which showed a preponderance of the masculine 
sex: control patients included 152 males (61%) and 97 females 
(49%); the Gram-negative group was composed by 41 males 
(55%) and 34 females (45%) meanwhile the Gram-positive 
group gathered 70 males (61%) and 44 females (39%; Table 1).
On the day of the first identification of microbiological 
growth in blood cultures, PCT levels were significantly higher 
in patients with Gram-negative bacteria comparing to con-
trols and patients with Gram-positive bacteria; the differences 
between controls and Gram-positive infected patients did not 
reach statistical significance (Table 2).
Figure 1 depicts box-plots for PCT levels in the first day of 
microbiological identification, clearly showing higher values 
for patients in the Gram-negative group in relation to con-
trol group and to Gram-positive group while the difference 
between these later groups is not evident.
The maximum value of the Youden index was 0.31, for a 
cutoff = 0.57 ng/ml. This cutoff reached a sensibility of 63% 
and a specificity of 68%; the corresponding positive predictive 
value was set in 57% and the corresponding negative predic-
tive value achieved 74% (Table 3). This was the optimum PCT 
cutoff, corresponding to the maximum point of the ROC 
curve: higher ones were associated with lesser sensitivity and 
lower ones led to loss of specificity.
ROC curve is presented in Figure 2. The AUC showed a 
significant accuracy for Gram-negative discrimination  from 
Gram-positive: AUC  =  0.687, with 95% confidence 
interval = 0.609–0.765.
Subgroup analysis was performed including the most 
frequent Gram-negative and Gram-positive microorgan-
isms responsible for sepsis in this sample of patients. In 
the Gram-negative group, the mostly frequently isolated 
agent was Pseudomonas aeruginosa, as it would be expected 
according to its great prevalence in many burn units, fol-
lowed by Acinetobacter spp. and other nonfermentative bac-
teria, including Burkholderia cepacia and Stenotrophomonas 
maltophilia. The Enterobacteriaceae were also very com-
mon, namely Escherichia coli, Enterobacter spp., Klebsiella 
pneumonia, Serratia marcescens, Proteus mirabilis, etc. 
From the Gram-positive group, Staphylococcus epidermidis, 
Staphylococcus hominis and other coagulase-negative species 
of Staphylococci, some of them without more specific iden-
tification furnished by the laboratory, were the most isolated 
from the blood samples. As it happened with Bacillus spp. and 
Corynebacterium spp., most of times the coagulase-negative 
species of Staphylococci species were suggested to be proba-
ble contaminants in the microbiological results and sensibil-
ity tests. Group D Enterococci (namely Enterococcus faecalis 
and Enterococcus faecium) and Staphylococcus aureus were also 
very frequently isolated and there were also isolations of 
Streptococcus spp. Table 4 displays the list of the most common 
microorganisms and the corresponding values of PCT levels 
on the first day of microbiological identification. The full list 
can be found in Supplementary Annex I.
Despite the presence of several outliers, it was found that 
PCT levels in the Gram-negative group were in general signif-
icantly higher comparing to controls, what did not happen in 
the Gram-positive group, with the exception of patients with 
sepsis due to Streptococcus spp. (Figure 3). With the exception 
of those with sepsis due to this Gram-positive species, which 
isolation is rare ate CBU, in almost all patients with PCT con-
centrations above 3.00 ng/ml on the day of collection of the 
first positive blood culture, the causative microorganism was a 
Gram-negative agent.
In the first case, the statistical difference was more pro-
nounced for glucose nonfermenting bacilli (particularly 
Acinetobacter, Pseudomonas, and Burkholderia spp.) and for 
E. coli and K. pneumoniae, glucose fermenting rods from the
Enterobacteriaceae family. Among patients with sepsis due to
Gram-positive cocci, PCT levels only reach statistically signifi-
cant difference for Streptococcus spp., as referred, but there was
a trend for significance for Enterococcus spp. and for S. aureus
(not visible for nonaureus species).
DISCUSSION
The statistical analysis of PCT levels on the first day of micro-
biological identification in blood samples in this sample 
Table 1. Population characteristics
Controls Gram-Negative Sepsis Gram-Positive Sepsis P
Number of Patients 249 75 114 —
Age (years)
Median 62.0 66.0 69.0
.392*Q1–Q3 45.5–78.0 44.5–79.5 47–80.0
Sex
Males 152 (61%) 41 (55%) 70 (61%)
.578†Females 97 (49%) 34 (45%) 44 (39%)
Procalcitonin 
(ng/ml)
Median 0.20 0.75 0.32 .000*
Q1–Q3 0.11–0.84 0.35–4.15 0.16–0.87
*Kruskall–Wallis test.
†Chi-square test.
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of extensively burned patients confirmed previous reports 
demonstrating significantly higher values in the presence of 
Gram-negative bacteria comparing with controls or patients 
with Gram-positive sepsis.10–13 The difference was most pro-
nounced when causative agents were glucose nonfermenting 
bacilli, particularly Acinetobacter and Pseudomonas spp., or 
Enterobacteriaceae rods, like E.  coli or K.  pneumoniae. On 
the other hand, a statistical difference in PCT levels was not 
found between in PCT levels of patients with sepsis caused by 
Gram-positive bacteria and control patients, with the excep-
tion of patients with sepsis caused by Streptococcus spp.
The results of this work are consistent with medical litera-
ture. Opal and Cohen14 attributed the different characteris-
tics of sepsis caused by Gram-negative and Gram-positive to 
the different constitution of their respective cell membranes, 
which will trigger different immunological responses and are, 
in most part, correlated with diverse clinical presentations and 
outcomes.15 Briefly explaining, despite there is not yet a full 
understanding of the mechanisms involved in cytokines acti-
vation following microbial insult, it is consensual that human 
innate immune cells (macrophages, neutrophils, dendritic 
cells) have receptors, present either on the external cell mem-
brane or inside the cytoplasm (endosomes) which are apt to 
recognize specific circulating molecular patterns. These pat-
tern recognition receptors (PRRs) can be activated by molec-
ular patterns resulting from nonmicrobial tissue damage 
(damage-associated molecular patterns, DAMPs) or by those 
exclusively corresponding to microbial pathogenic compo-
nents (pathogen-associated molecular patterns, PAMPs).16 
The interaction between PRRs and PAMPs induces the release 
of cytokines by immune cells, initiating the septic process.
There are several types of PRRs, including Toll-like recep-
tors (TLRs) and NOD-like receptors—mainly activated 
by bacteria; RIG-I-like receptors and DNA-sensing mol-
ecules—crucial for sensing of viruses; C-type lectin receptors 
responding to fungi and mycobacteria PAMPs; etc. The outer 
membrane of Gram-negative bacteria cell wall is composed 
mostly by lipopolysaccharide, frequently referred as endotox-
ine, which is its principal PAMP, being recognized by TLR4.17 
Instead of lipopolysaccharide, PAMPs of Gram-positive bacte-
ria cell wall are basically lipoteichoic acid,18 lipoproteins and 
proteoglicans, mostly sensed by TLR2.
TLR4 activation triggers a strong release of inflammatory 
cytokines, namely tumor-necrosis factor α, interleukin-1, and 
interleukin-6.19 These cytokines will promote gene transcrip-
tion leading to PCT secretion from extrathyroidal tissues, with 
abrupt rise of its blood levels. It was also described a direct 
stimulation of PCT secretion by circulating endotoxins.20 On 
the other hand, TLR2 activation usually induces a relatively 
weaker and not always straightforward production of those 
cytokines, varying according to different pathogens by not 
well known reasons.
In 2008, Charles and colleagues analyzed the accuracy of 
PCT measurements to discriminate between Gram-negative 
and Gram-positive bacteremia at the onset of bloodstream 
infection, concluding that serum levels were greater in the 
100
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Figure 1. Box-plots for procalcitonin levels in controls (n = 249), Gram-negative (n = 75), and Gram-positive (n = 114) sepsis patients groups.
Table 3. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of procalcitonin cutoffs for 
the distinction between Gram-negative and Gram-positive sepsis in burn patients
Cutoff Sensitivity (%) Specificity (%) PPV (%) NPV (%) Youden Obs.
0.50 64 62 53 72 0.26
0.57 63 68 57 74 0.31 Max. Youden
1.00 46 76 52 71 0.22
5.00 23 92 62 68 0.15
Table 2. Pairwise comparisons for procalcitonin levels 
between sepsis groups
Comparison P
Gram-negative septic patients vs controls .000
Gram-negative septic patients vs Gram-positive septic patients .000
Gram-positive septic patients vs controls .153
Mann–Whitney test with Bonferroni-corrected P-values.
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first group, with an AUC of 0.79, opposing to what happened 
with the measurements of C-reactive protein and leucocyte 
counting.21 As PCT levels determination is available sooner 
than Gram stain results and microbiological identification, 
these authors suggest this information should be taking in 
account when choosing empirical antibiotherapy for sepsis.
In 2012, Jeong et al,22 showed a good performance of PCT 
in the distinction between patients with negative and positive 
blood cultures, facilitating the differentiation of true blood-
stream infections from contamination. They also reported 
that significantly higher values were found for Gram-negative 
bacteremia comparing to Gram-positive or fungal ones, what 
did not happen with C-reactive protein values. With most 
patients coming from hematological ICUs, an article by 
Brodská et al23 described significantly higher PCT values for 
patients with Gram-negative bacterial infections, comparing 
to Gram-positive or fungal infections, meanwhile no statistical 
difference was found between these latter two groups. They 
concluded that PCT levels could be used to help the confir-
mation or exclusion of Gram-negative sepsis. Nakajima et al,24 
presented similar results in 2014, speculating the possibility of 
using PCT levels to help antimicrobial empiric antibiotherapy.
In 2015, Oussalah et al25 using a comprehensive electronic 
database, performed an observational cross-sectional study 
and analyzing 2699 patients with positive blood cultures, 
found statistically higher PCT levels in patients with Gram-
negative sepsis comparing patients with Gram-positive sepsis, 
with most elevate values for Escherichia spp., Bacteroides spp., 
Klebsiella spp. and Enterobacter spp. They also pointed values 
under 0.75 ng/ml as very effective for exclusion of most clin-
ical relevant pathogens, meanwhile a cutoff above 10 ng/ml 
practically excluded the hypothesis of sample contamination or 
fungal infection. In a prospective study, including 1949 adult 
patients with positive blood cultures, Leli et al26 also reported 
significantly higher PCT levels for Gram-negative infections, 
more pronounced for Enterobacteriaceae bacteria, suggesting 
a cutoff of 3.1 ng/ml for the exclusion of these microorgan-
isms. Guo et al27 reached the same results in a sample of 280 
septic patients and listed Klebsiella, Escherichia, Acinetobacter, 
Enterobacter, and Pseudomonas as the pathogenic species 
responsible for higher PCT levels. In 2016, Li et al28 analyz-
ing 328 septic episodes, suggested that PCT levels might be 
used as a surrogate marker to distinguish sepsis cases origi-
nated by Gram-negative bacteria from the ones deriving from 
Gram-positive bacterial or fungal invasion of bloodstream, 
proposing a cutoff of 2.44 ng/ml. Yan et al29 reviewed data 
from 484 monomicrobial positive blood cultures of septic 
patients (75% collected at the ICU and 25% at the Emergency 
Department), reporting statistically significant differences 
in PCT levels, with higher values corresponding to patients 
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Figure  2. Receiver operating characteristic curve for procalcitonin 
accuracy in the distinction between Gram-negative and Gram-positive 
bacterial sepsis in burn patients (cutoff = 0.57 ng/ml).
Table 4. Procalcitonin values for the most frequently isolated groups of microorganisms in blood samples of septic burn patients
Microorganism Number Median Q1 Q3 P
Controls 249 0.20 0.11 0.84
Glucose nonfermenting Gram-negative Bacilli
Acinetobacter spp. 13 1.17 0.49 7.30 .002
Pseudomonas spp. 13 0.67 0.39 1.68 .005
Burkholderia cepacia 4 1.82 0.89 3.05 .045
Xanthomonas maltophilia 4 0.63 0.29 8.89 .241
Enterobacteriaceae
Enterobacter 9 0.55 0.22 0.62 .087
Escherichia coli 5 2.96 0.75 6.90 .020
Klebsiella pneumoniae 5 1.77 0.58 22.18 .043
Serratia marscecens 5 0.75 0.48 0.89 .255
Gram-positive Cocci
Enterococcus spp. 12 0.38 0.18 0.73 .177
Staphylococcus aureus 11 0.28 0.21 0.97 .185
Staphylococcus (except aureus) 54 0.29 0.11 0.88 .668
Streptococcus spp. 8 2.18 1.27 4.91 .003
Mann–Whitney test (comparison with control).
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with Gram-negative infection. From the Gram-negative bac-
terial sepsis group, PCT levels were more pronounced for 
Enterobacteriaceae microorganisms (E.  coli, Kebsiella spp., 
Enterobacter spp., and Serratia spp., by this order), which 
presented relatively higher values than glucose nonfermenting 
Gram-negative bacilli (P.  aeruginosa, Acinetobacter bauma-
nii, S. maltophilia, B. cepacia, etc.). From the Gram-positive 
bacterial sepsis group, patients infected by Streptococcus spp., 
Enteroccoccus spp., and S. aureus had the most elevated PCT 
concentrations. The authors defended that PCT could be use-
ful not only to distinguish between Gram-negative and Gram-
positive sepsis, but might even be employed to identify diverse 
species inside each of these groups of microorganisms.
In a work from 2018, Thomas-Rüddel et al performed a sec-
ondary analysis of a prospectively collected dataset, including a 
very large sample with 4858 septic patients from 40 hospitals. 
Their results were very similar to the present study, showing 
distinctly higher values for PCT concentrations in patients with 
Gram-negative bacteremia than in patients with sepsis result-
ing from Gram-positive or fungal systemic invasion.30 Indeed, 
the AUC for the discrimination of Gram-negative sepsis from 
Gram-positive was identical, is spite substantially diverse cut-
offs. Subgroups of pathogens with the most elevated values 
were also very close, with Streptococcus spp.; E.  coli, Proteus 
spp., K. pneumoniae and other Enterobacteriaceae on the top. 
The authors referred, however, a large overlap of PCT levels 
and speculate that higher values may be more related with 
higher bacterial load and potentially with intrinsic character-
istics of pathogens groups, considering the discriminatory 
power too low to guide therapeutic decisions.
Burn patients have a risk of infection superior to the aver-
age critical care patient and sepsis diagnosis is more difficult31 
due to the intense inflammatory systemic response unleashed 
by the  burn insult per se. In these patients, PCT measure-
ments, particularly using a kinetic approach, have being 
increasingly advocated by many authors to help the differ-
entiation between pure inflammatory reaction and microbial 
infection32–36 and for antimicrobial stewardship.37 However, 
this strategy is still not fully accepted38–42 in spite of systematic 
reviews and meta-analysis suggesting its validity.43–45 In 2012, 
a study of Lavrentieva et al,46 including 86 burn patients, was 
presumably the first work reporting statistically significant 
differences of PCT levels between burn patients with Gram-
negative sepsis and those with Gram-positive sepsis, with the 
most elevated values in the former group. Mokline et  al in 
a paper of 2015,47 including 44 patients, confirmed these 
results.
To the authors’ knowledge, the present work, with 189 
septic burn patients, from a homogenous population, cor-
responds to the largest sample already analyzed in medical 
literature regarding this subject. It confirms previous reports 
and, moreover, it further details subgroups differences. On 
its strengths one can also count the use of strict and inter-
nationally validated criteria for definition of burn sepsis, as 
well as the exclusive utilization of microbiological positive 
bloodstream cultures, collected in a standardized way, avoid-
ing potential bias due to the use of other types of biologi-
cal samples. The results of this study, with PCT showing a 
fair capacity for the distinction between Gram-negative and 
Gram-positive sepsis insinuate the possibility of using its val-
ues in face of sound suspicion of sepsis in burn patients to help 
the choice of empirical therapy until definitive microbiological 
identification is available. Cutoffs will be clearly dependent on 
the idiosyncratic characteristics from each facility, depending 
on its nosocomial flora and its patients and cannot be gener-
alizable. However very high PCT levels (for instance, above 
3.00 or 5.00 ng/ml) would usually be more associated with 
Gram-negative sepsis, with fair positive predictive value and 
negative predictive value, and good specificity in spite outliers 
may be present. Also, in the great majority of the cases, PCT 
values under 0.5 ng/ml will not correspond to Gram-negative 
infections but to Gram-positive or fungal ones.
Paying attention that the majority of deaths in burn 
patients result from infectious episodes and sepsis48 is clear 
that prompt, adequate and appropriate selection of antimi-
crobial therapy is crucial for the outcome of these high risk 
patients. On the other hand, potential damages from adverse 
events and the contribution to the development of microbial 
resistance due to superfluous antimicrobial therapy must be 
duly considered. Meanwhile faster methods of microbiolog-
ical identification, such as polymerase chain reaction,49 mass 
spectrometry ionization (Matrix-Assisted Laser Desorption 
Ionization–Time of Flight), gene expression profiling, aptam-
ers panels, etc.,50 or even more sophisticated and individual-
ized system-based ones (integrating genomics, metabolomics, 
and proteomics data), are not either widely available or fully 
developed,51–53 PCT dosing will remain one of the more use-
ful tools to help clinicians decisions.5,54,55
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Figure 3. Box-plots for procalcitonin levels in Gram-negative and Gram-positive bacterial sepsis subgroups.
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For these reasons, in the authors’ opinion, it is worthwhile 
to use PCT measurements to have a more empowered pre-
scription decision, even bearing in mind that the analysis of its 
levels does not fully ensure the desirable degree of precision.
The present work has manifestly some limitations that should 
be noticed. First, being a retrospective study it is more prone 
to selection bias than a prospective one. On the other hand, 
all patients enrolled came from the same center, so the results 
obtained may not be exactly reproduced in other Burn Units. 
Subgroup analysis according to associated pathologies was not 
done, neither the results from other current biomarkers like 
CRP or leucocyte counting were noted. However, according to 
the available literature, the relevance of these biomarkers is at 
least very questionable for the purposes of this study. Due to the 
small number of positive blood samples with fungi found during 
the study period, comparison with PCT levels in Gram-negative 
and Gram-positive sepsis was not done. To avoid confusion, 
mixed infections were purposely not included. It would also had 
been very interesting to further extend the analysis of PCT levels 
to the subsequent days after the positivation of blood samples, 
assessing the potential added value of PCT kinetics regarding 
distinction of different types of bacterial infection.
CONCLUSIONS
This retrospective study consistently showed the presence 
higher PCT levels in burn patients with Gram-negative sep-
sis, suggesting that PCT may help clinicians in the choice of 
the empirical antimicrobial therapy, while the definitive, gold 
standard, microbiological culture results and sensibility tests 
are not yet available. However, it should be emphasized that 
PCT must be integrated within the clinical context and the 
facility prevalent flora, and it can never substitute clinicians’ 
evaluation and judgment. Prospective multicentric studies are 
needed to get a stronger validation of the use of PCT values 
for the distinction between Gram-negative and Gram-positive 
bacterial sepsis and it would be also desirable to include fungal 
and mixed infections. Evaluation of PCT kinetics potential for 
differential diagnosis between microbial sepsis due to diverse 
types of pathogens would also be very interesting and poten-
tially useful for clinical practice.
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Discussion and conclusions 
The main objective of this thesis was to investigate the potential role of procalcitonin (PCT) as 
part of antimicrobial stewardship in Burn Units. Being the first cause of death in burn patients 
[1], and also responsible for huge increments in hospitalization costs [2], the importance of 
sepsis and the need of its adequate diagnosis and treatment, was addressed in the 
Introduction chapter. The increased risk of infection and the higher mortality in these patients 
compared to unburned septic patients [3,4] was underlined. In fact, the loss of tegument and 
the immunodepression together with the need of invasive devices to manage by severe burns 
facilitates microbial invasion [5]. In order to achieve the best outcomes it is crucial to start an 
effective antimicrobial therapy as soon as possible [6]. At same time, the overwhelming 
problem of microbial resistance, mostly resulting from superfluous ministration of 
antimicrobial drugs [7], creates a challenging diagnostic task for physicians who dealt with 
these patients, tacking in account that classical signs of sepsis lose most of their accuracy due 
to the marked inflammatory systemic response unleashed by burn trauma [8,9,10]. 
Hemocultures are still the gold standard for sepsis diagnosis, but in most facilities 48-72 hours 
are necessary to get results, which, on the other hand, are positive in only 20-30% of actually 
septic patients [11,12]. In this context, and never dispensing a rigorous clinical examination, 
the use of biomarkers may empower clinicians’ ability to manage sepsis during all the stay of 
the patients in Burn Units. In this field, procalcitonin, secreted virtually by all parenquimatous 
cells after stimuli by endotoxin or cytokines after microbial invasion, has been suggested by 
several authors as one of the most reliable biomarkers in the distinction of infectious and 
noninfectious processes in critical patients [13,14,15], including the victims of burns [16]. Its 
levels rise abruptly with sepsis, being detectable in blood few hours after the insult and are 
closely relate with microbial inoculum and disease severity [17,18].  
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As a first step to evaluate its actual feasibility in burn patients, medical literature was 
thoroughly reviewed and a meta-analysis on the use of PCT for sepsis diagnosis was 
performed, including 12 trials performed from 1997 to 2015, showing that burn sepsis patients 
had a statistical significant increase in the PCT mean values, in comparison with non-sepsis 
patients, and also that there was an association between increased PCT levels and the 
occurrence of mortality. To overcome the heterogeneity of the studies regarding sample sizes, 
inclusion criteria and methodologies, a random-effects model was employed. The pooled 
results showed an AUC in the ROC curve of approximately 0.87, which is a good result, taking 
in consideration that the paucity of works in this subject has led to the inclusion of paediatric 
patients, where PCT has shown worse performance which is probably related to the 
physiological peculiarities of this age group. To reinforce the precision of the analysis, a 
bubble-plot was also done, identifying the two older studies, performed with less accurate 
technology, as the ones presenting most of outliers values, and pointing a cut-off value of 1,5 
ng/mL for sepsis diagnosis. This meta-analysis strongly suggests that PCT may be considered as 
a biomarker with good diagnostic ability to discriminate between the septic and the non-septic 
burn patients, particularly when serial and frequent measurements are performed. 
Chapter 3 presents a retrospective observational study including 150 burn patients with TBSA 
≥ 15% from Coimbra Burns Unit, admitted from January 2011 to December 2014. Using ABA 
sepsis definition, which combines 3 or more clinical signs of sepsis, with specific cut-offs for 
burn patients with documented infection [19], 102 patients were deemed to have sepsis and 
48 were on the non-septic group. Compared to traditional biomarkers (leucocyte and platelet 
countings, prothrombinemia, D-dimers, C-reactive protein, serum lactate and temperature) 
ROC curves analysis showed that PCT was the most reliable for an early diagnosis of sepsis. It 
must be referred that the isolated use of clinical scores for the diagnosis and stratification of 
burn sepsis patients is not warranted in the literature as in other pathologies. For instance, the 
Sequential Organ Failure Assessment score (SOFA) [20], one of the most used means to 
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estimate sepsis complications has not been validated for burn patients complications and even 
ABSI (Abbreviated Burn Severity Index) [21] or BOBI (Belgian Outcome in Burn Injury Index) 
[22], purposely designed for prognosis determination in burn patients have limited interest, 
and namely do not specifically address sepsis. On the other hand, usual infection biomarkers, 
like leukocytes and platelets counting, coagulation changes and temperature lose their 
diagnostic power due to systemic inflammatory response triggered by severe burns, while C-
reactive protein (an acute-phase protein synthesized by the liver) has not enough specificity 
for infection and has a unfavourable kinetic profile [23]. The rise in serum lactate levels (in the 
form of L-lactate, the most common used) either produced by anaerobic metabolism of 
glucose related to cellular hypoxia, being above all a marker of hypoperfusion, as traditionally 
described or, according to a more recent alternative hypothesis, resulting from an accelerated 
aerobic glycolysis driven by adrenergic stimulation induced by inflammation, independently of 
hypoxia [24], also lacks the specificity for sepsis. In this setting, and after rigorous clinical 
assessment, the determination of PCT, preferably in a seriated approach, is nowadays the 
most effective and practical way for the diagnosis of sepsis in burn patients. Following the 
results of this study, an alert cut-off of 0.5 ng/mL was proposed, indicating the need for daily 
PCT assessment, with empirical antimicrobial therapy recommended for levels above 1.0-1.5 
ng/mL. 
In Chapter 4, the use of PCT to establish the prognostic of burn patients, as well as its capacity 
to reflect their response to antimicrobial therapy, is assessed in a study exclusively including 
101 septic burn patients (68 survivors and 33 non-survivors). The analysis used samples 
sequentially collected along the stay of patients at CBU: 2-3 times a week and even daily in 
some seriously ill patients. Using Friedman’s test to survey time variations, the results 
demonstrated that PCT had a close and statistically significant association with clinical 
outcomes, with higher values corresponding to higher mortality. It was also found that the 
persistency of abnormally elevated PCT levels during the days of antimicrobial therapy was 
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linked with therapeutic failure, due to antimicrobial drugs inefficacy or/and inadequate 
debridement of infectious foci, opposed to what happened when PCT levels fell in a consistent 
way, indicating therapy efficacy and supporting the decision of stopping antimicrobial therapy. 
Chapter 5 addresses the effect of the inflammatory changes directly resulting from tecidular 
trauma provoked by thermal or surgical insult on the accuracy of PCT for sepsis diagnosis. For 
this purpose, an observational retrospective study including 145 CBU patients and 283 surgical 
interventions in the first five days after burn injury and burn surgery was performed. In the 
acute phase of burns, corresponding to the first five days after burn insult, daily PCT levels 
were significantly more elevated in septic patients, usually above 1,0 ng/mL, peaking at the 
second day and declining after it, usually reaching normal values by the fifth day if the 
infection was controlled. The discriminatory power regarding non-infectious systemic 
inflammation increases with time, being higher by the fifth day. After the usual surgical 
interventions usually undertaken at Burn Units (escharectomies, skin grafts, pedicled or free 
flaps, amputations, etc.), PCT levels followed a similar pattern and the discriminatory power 
increased again from the first to the fifth day. It is important to notice that when sepsis is 
under control there is only and a mild effect of isolated tecidular trauma on PCT levels, which 
is self-limited, provoking a small peak by the second day, which quickly subsides, returning to 
previous values by the fifth day. Moreover, this kinetics is independent of the existence or 
absence of sepsis preoperatively, being foreseeable if PCT levels before the intervention are 
known.  These results deny the misconception that inflammatory changes related to the 
systemic inflammatory response associated with burn or surgical trauma were a reason to 
preclude the use of PCT in the management of burns sepsis. On the contrary, they suggest that 
PCT kinetics may be of great value for the discrimination between true sepsis and burn-
associated early inflammatory response as well as for the diagnosis of postoperative sepsis in 
these patients.  
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Finally, the role of PCT for the distinction between sepsis produced by Gram-negative and 
Gram-positive bacteria in burn patients is assessed in Chapter 6. In another study with septic 
patients from CBU, PCT levels in the day of the first microbiological identification of 
hemocultures were related with the specific pathogens. PCT levels were significantly higher in 
75 burn patients with Gram-negative sepsis comparing to 114 patients with Gram-positive 
sepsis and 249 controls (corresponding to negative hemocultures), but did not reach 
significance between patients with Gram-positive sepsis and controls, as indicated by pairwise 
comparisons using Mann-Whitney tests with Bonferroni correction. These differences on PCT 
levels according to Gram type of bacteria explained by their different cell wall composition, 
whose antigens (PAMPs) trigger different receptors in the innate immunity cells, stimulating a 
greater or smaller production of procalcitonin [25,26]. In the ROC curve the accuracy for Gram-
negative bacteria reached an AUC of 0.687. Subgroup analysis showed that the most elevated 
levels occurred in patients with sepsis caused by non-fermentative Gram negative bacteria, by 
Klebsiella pneumoniae and, in a lesser extent, by other Enterobacteriaceae. On the other hand, 
for the majority of the cases, PCT values bellow 0.5 ng/mL almost excluded infections due to 
Gram negative bacteria, while an initial value above 3.0 ng/mL was rare in Gram positive 
sepsis. Despite its accuracy lacks the desirable precision, when coupled with knowledge of 
nosocomial flora of the burn unit, PCT levels may still provide initial guidance for the choice of 
empirical antimicrobial therapy. 
 In short, this thesis shows that PCT has several characteristics that recommend its use to help 
clinical decisions at diverse moments of burn patients’ management. Similarly to what occurs 
in other clinical contexts, PCT is not yet the “ideal sepsis biomarker” and it should not replace 
other mandatory elements of diagnosis, namely a detailed anamnesis and a thorough clinical 
examination, but its value is clearly demonstrated. In burn patients, PCT values are related 
with sepsis severity and patient prognosis, allowing a stratification of the healthcare needs. On 
the other hand, the analysis of PCT kinetics may facilitate the distinction between true ongoing 
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sepsis and a physiologic inflammatory reaction in the first days after burn injury and after 
surgical procedures. When sepsis is present, PCT levels were found to be significantly higher in 
patients with Gram-negative sepsis comparing to patients with Gram-positive sepsis and 
controls. In this situation, antimicrobial therapy must start before definitive identification of 
causative agents and susceptibility tests, and PCT levels may help the initial choice of the 
antimicrobial and the assessment of its efficacy. 
Besides the need of accuracy to indicate the individual risk for sepsis, the main goal in the use 
of a biomarker is obviously to achieve an improvement in the health of the patient [27]. This is 
to say that the relevancy of the test, whether it changes clinical decision making [28] and/or 
treatment implementation and monitoring [29], resides on the actual benefits for the patients 
resulting from its application [30]. Attending to the pathophysiologic characteristics of burn 
patients, while faster, more trustable and cheaper methods of microbiological identification 
are not either widely available nor fully developed [31,32,33,34], repeated PCT measurements, 
empowering prescription decisions, should be included in antimicrobial stewardship programs 
in Burn Units in order to increase antimicrobials effectiveness, reduce morbidity and mortality, 
avoid adverse events and development of microbial resistance, and minimize costs. 
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